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ABSTRACT 
The objective of this research was to assess ultrasound image attributes of human 
dominant ovarian follicles in the final stages of development during natural and oral 
contraceptive (OC) cycles, as well as characterize ovarian follicular and endometrial 
development during and after continuous versus conventional dosing schemes.  We 
utilized sophisticated computer algorithms to elucidate an association between image 
attributes and physiologic status of follicles in their final stage of development.  We used 
transvaginal ultrasonography to quantify changes in the numbers and diameters of ovarian 
follicles and changes in endometrial thickness and pattern during and following 
discontinuation of two different regimens of OC.  Developmental changes in ovarian 
follicles and corpora lutea were correlated with serum estradiol-17β and progesterone, 
respectively to provide a comprehensive approach to examining ovarian and uterine 
function.   
We reported for the first time that follicles which develop during natural and OC 
cycles have similar image attributes, which provides preliminary evidence that image 
attributes of human follicles are associated with physiologic status during the growth phase.  
Further research should be performed to elucidate the exact correlation between image 
attributes during all stages of follicular development throughout the menstrual cycle, 
prediction of dysfunctional follicular development (i.e., hemorrhagic anovulatory follicles) 
and the effects of different OC formulations on follicle development.  Once the 
association between image attributes and various scenarios of follicular development are 
determined, a computer program could be developed to assess follicular health with a 
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single ultrasound examination, obviating many ethical constraints that currently prevent 
large scale progress in ovarian follicular research. 
We further documented that continuous OC administration schemes provide 
greater follicular suppression than conventional dosing schemes.  No dominant follicles 
developed during three consecutive 28 day cycles of continuous OC use, whereas eight 
dominant follicles developed during the same time period of conventional OC use.  We 
interpreted these findings to mean that continuous OC dosing schemes provide a more 
effective contraceptive with a decreased risk of “escape” ovulation compared to 
conventional dosing schemes.  Most follicles ovulated in the immediate cycle following 
discontinuation of OC.  We suggest that the delay to fertility following cessation of OC is 
not due to anovulation but other yet, unknown, biological factors.  
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Chapter 1 
GENERAL INTRODUCTION 
1.1 Human Ovarian Follicular Dynamics  
The study of reproductive medicine and biology, arguably, began in 1672 when the 
Dutch anatomist, Regnier de Graaf (1641-1673), discovered the ovarian follicle and 
ovulation1.  de Graaf, mistakenly defined the fluid-filled follicle as the oocyte and was  
corrected in 1827 by Karl Ernst von Baer, when von Baer described the follicle-enclosed 
“ovulum”, which later became known as the “Graafian Follicle”2.  The form and function 
of the ovaries and uterus have been under examination since de Graaf’s documentation of 
ovarian follicles.  However, modern investigations involve novel techniques, such as the 
biomicroscope; a union between ultrasonography and microscopy.  We have come a long 
way to understanding the intricacies of uterine and ovarian physiologic function and 
anatomy through these investigations, but we are far from completely understanding the 
physiologic function and microscopic anatomy of the reproductive organs and how their 
form and function affect women’s reproductive health.   
Introduction of the first Food and Drug Administration approved oral 
contraceptive (OC), Enovid™, in the early 1960's, heralded a contraceptive revolution for 
women.  Prior to the introduction of Enovid™, women had fewer, less efficacious 
contraceptive choices.  Only three major changes have been made to OC formulations in
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the last 40 years; these changes include: (i) a decrease in the concentration of synthetic 
hormones contained in each pill, (ii) a switch from manestrol to ethinyl estradiol (EE) and 
(iii) the introduction of new, different progestin formulations.  We do not yet fully 
understand the exact physiologic mechanisms of action associated with the suppression of 
follicular growth and endometrial development during OC administration.    
The research in this thesis focuses on the ultrasound image attributes of dominant 
ovarian follicles that develop during natural and OC cycles as well as ovarian follicular 
dynamics and endometrial development during and following discontinuation of 
continuous and conventional OC dosing schemes.  This review examines the current data 
pertaining to ovarian folliculogenesis during natural cycles and OC administration.  
Furthermore, the review briefly examines the principles of ultrasound imaging and image 
analysis techniques. 
1.1.1 Oogenesis and Primordial Follicle Development 
The formation, development and maturation of an ovum, or oogenesis, occurs 
completely during fetal life; thus, a female is born with her complete complement of 
oocytes and is incapable of producing more during her reproductive life-span3.  Oogenesis 
begins during the third week of gestation when primordial germ cells migrate from the yolk 
sac entoderm to the genital ridge under direction of unknown cellular mechanisms and 
chemotaxic factors4.  Arrival of the primordial germ cells at the primordial gonadal 
structure is associated with the differentiation and maturation of the embryonic ovary and 
redefinition of the primordial germ cells to oogonia4.  Interestingly, gonadal development 
will not occur in the absence of germ cells4.  Oogonia division continues until the twentieth  
week of gestation, when approximately 7 million oogonia are present; thereafter, oogonia 
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enter meiosis in response to factors produced by the rete ovarii3,5,6.  Once oogonia enter 
meiosis, they are redefined as primary oocytes and remain arrested in the diplotene stage of 
meiotic prophase I (32 µm in diameter) until stimulated to resume meiosis during the 
ovulatory process of a woman’s ovarian cycle4,7. 
Follicular development begins during the sixteenth week of gestation when spindle-
shaped pre-granulosa cells envelope the primary oocyte in a single layer7.  An outer layer of 
collagen, known as the basal lamina, forms around the pre-granulosa cell layer7.  The entire 
primitive structure is defined as the primordial follicle.  Although some primordial follicles 
will begin growing immediately, the majority remain in a resting state until they either 
degenerate, or enter the growing phase6.  The population of arrested primordial follicles 
constitutes the ovarian follicular reserve or resting pool of follicles (approximately 2.7 x 105 
to 4.7 x 105 follicles at menarche) that provides a woman with her complete follicle 
complement for her entire reproductive life3. 
1.1.2 The Population of Pre-antral Follicles 
The population of non-growing follicles is comprised of four types of follicles:     
(i) primordial follicles (35.0 µm in diameter) are composed of a primary oocyte surrounded 
by flattened granulosa cells,  (ii) intermediary follicles (38.0 µm in diameter) are composed 
of a primary oocyte surrounded by flattened and cuboidal granulosa cells, (iii) primary 
follicles (46.0 µm in diameter) are composed of a primary oocyte and a single layer of 
cuboidal granulosa cells and (iv) secondary follicles (77.0 µm in diameter) are composed of 
a primary oocyte surrounded by more than one layer of cuboidal granulosa cells7,8.  The 
majority of follicles residing in the non-growing pool are primordial and intermediary 
follicles10.  True follicular growth does not occur until the germinal vesicle reaches 19 µm 
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in diameter during the secondary follicle stage of development9.  Approximately 1000 
follicles are lost from the resting pool each month until the age of 35 after which the rate 
of loss increases such that by menopause 100 to 1000 resting follicles remain within the    
ovaries11-14.  Follicular growth and development from the primordial follicle to ovulation is 
illustrated in Figure 1.1. Morphologic changes associated with each stage of development 
are summarized in Table 1.1 
1.1.3 Initiation of Follicular Growth  
The exact mechanisms and factors responsible for initiation of follicular 
development are poorly understood; however, the process is considered to be multi-phasic  
and regulated by biological molecules that act on the oocyte and/or granulosa cells6.  It is 
unclear if initiation of follicular growth is due to the release from inhibitory factors or 
stimulation by activating factors.  Available evidence suggests that a balance between 
inhibiting and activating factors produced by the pre-antral follicles and/or factors present 
in the ovarian microenvironment are responsible for initiating follicular growth.  
A number of factors have been implicated in initiating follicular growth, including; 
epidermal growth factor, insulin-like growth factor, transforming growth factor, and 
fibroblast growth factor as well as factors which stimulate cyclic adenosine monophosphate 
(cAMP) production including vasoactive intestinal peptides, pituitary adenylate cyclase 
activating peptide and neurotropins such as nerve growth factor brain-derived 
neurotrophic factor and neutrophin-46,15.  Conversely, Anti-Müllerian hormone and 
somatostain are suggested to inhibit the initiation of follicular growth6.  The rate at which 
resting follicles are stimulated to grow is reported to be directly proportional to the number  
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Figure 1.1: Classification of follicles in the human ovary (From Gougeon, 1996) 
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Table 1.1: Morphological changes associated with each stage of follicular development 
       (From Gougeon, 1996) 
 
 
Stage of 
Development 
Mean Follicle 
Diameter 
Morphological Characteristics 
Primordial Follicle 35 µm • Single layer of flattened granulosa cells 
Intermediary 
Follicle 
38 µm • Single layer of flattened and cuboidal 
granulosa cells 
Primary Follicle 46 µm • Single layer of cuboidal granulosa cells zona 
pellucida 
Secondary Follicle 77 µm • >1 layer of cuboidal granulosa cells 
• FSH, estrogen and androgen receptors are 
expressed in granulosa cells 
• LH receptors expressed on theca interna 
• Theca interna and externa begin to 
differentiate 
• Differentiation of follicular vascular and 
lymphatic circulatory systems 
 
 
Class 1 0.1 - 0.2 mm • No antrum 
• Two-cell-two gonadotropin hormone 
synthesis occurs 
Class 2 0.2 - 0.4 mm • Cumulus oophorus develops 
• Antrum development commences 
• Call Exner bodies form in granulosa cells 
Class 3 0.4 - 0.9 mm • Small antrum 
Class 4 0.9 -  2.0 mm • Medium antrum 
Class 5 2.0 - 5.0 mm • Medium antrum 
• Recruitment occurs 
Class 6 5.0 - 10.0 mm • Medium antrum 
• Selection occurs 
• Aromatase activity detected in granulosa cells 
Class 7 10 - 16 mm • Large antrum 
Class 8 >16 mm • Ovulation 
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of follicles remaining in the resting pool and appears to be affected by testosterone, age, 
nutrition, activity of the thymus gland and opioid peptides16,17. 
1.1.4 Preantral Growth Phase or Basal Follicular Growth 
Follicles begin to enter the preantral growth phase during fetal development and do 
not stop entering this phase until menopause6,7.  The preantral growth phase begins with 
the progression of a primordial follicle (35.0 µm) into a primary follicle (46.0 µm) through 
the differentiation of spindle-shaped granulosa cells into cuboidal cells.  During this 
transition a mucopolysaccharide layer is synthesized and secreted by the granulosa cells 
and/ or primary oocyte to form a zona pellucida around the oocyte18 (Table 1.1).  Gap 
junctions traverse the zona pellucida between the granulosa cell layer and the oocyte to 
form a communication system between the cell types4.   Adherent and gap junctions also 
develop between adjacent granulosa cells forming a functional synctium that is essential to 
maintaining communication within the avascular granulosa cell layer6. 
Primary follicles are redefined as secondary follicles (≤120 µm)  when at least two 
layers of granulosa cells surround the primary oocyte and the ovarian stroma cells align 
parallel next to the basal lamina10 (Table 1.1).  Granulosa cells, of secondary follicles, 
express follicle stimulating hormone (FSH), estrogen and androgen receptors; however, 
these receptors are likely not fully functional4,19.  The surrounding stromal tissue 
differentiates into two theca layers, the inner theca interna and the outer theca externa, as 
the secondary follicle increases in diameter.  The theca interna, in secondary follicles, is 
composed of fibroblast-precursor cells containing luteinizing hormone (LH) receptors and 
a blood supply that contains one or two arterioles which terminate in a wreath-like fashion 
of capillaries adjacent to the basal lamina of the granulosa cells20,21.  The theca externa,  in 
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secondary follicles, is composed of undifferentiated theca cells4,22.  The secondary follicle 
may continue growing or undergo atresia:, with the latter occurring in most cases (>99%)23.   
1.1.5 Tonic Growth Phase 
The tonic growth phase is associated with a 15-fold increase in diameter through 
the conversion of a Class 1 (pre-antral) follicle (0.12-0.20 mm in diameter) into a Class 5 
follicle (2.0-5.0 mm in diameter)4.  Follicular growth and development during this phase are 
largely due to antral cavity formation, beginning during Class 2, and proliferation of 
granulosa and theca cells.  Antral cavity formation sustains follicular growth and 
development by providing a unique hormone micro-environment to the follicle and 
oocyte16.   The antral fluid is composed of protein-bound and free sex steroids, proteins, 
proteoglycans and electrolytes24.  The complete growth trajectory of a follicle from Class 1 
to Class 8 is diagrammed in Figure 1.2.  
Entry into the tonic growth phase is marked by the transition of a secondary follicle 
into a Class 1 follicle4, 25.  The transition into Class 1 occurs when at least one fibroblast-like 
stromal cell of the theca interna differentiates into an epithelioid cell26.  By Class 1 of 
follicular development, the follicle is capable of producing estrogen via the two-cell two 
gonadotropin relationship between theca and granulosa cells (Table 1.1).  Theca cells are 
stimulated by LH to produce androgens which cross the basal lamina into granulosa cells, 
where the androgens are aromatized by enzymes to estrogens and subsequently released 
into the follicular fluid, the intrafollicular space or the systemic circulation4,10. 
It takes approximately 25 days for Class 1 or pre-antral (0.12-0.2 mm in diameter) 
follicles to develop into Class 2 or early-antral follicles (0.2-0.4 mm in diameter; Figure 1.2). 
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Figure 1.2: Complete growth trajectory: conversion of a Class 1 follicle into a Class 8 
       follicle. Gn, Gonadotropin. (From Adashi et al., 1996). 
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If Class 1 follicular development began during the luteal phase than entry of the follicle 
into Class 2 would generally occur between days 11 and 14 of the late follicular phase of 
the following cycle4,25.  Gougeon suggested that increased levels of FSH during the late 
follicular phase are likely responsible for a peak in the population of Class 2 follicles10.  
Class 2 is marked by differentiation of granulosa cells and the formation of small antral 
cavities (0.04 mm in diameter) which eventually coalesce to form a single large antral 
cavity10 (Table 1.1).  Follicle stimulating hormone is suggested to induce antrum 
formation10,27,28.   Antrum formation subsequently results in the formation of the cumulus 
oophorus which is a stalk-like projection of granulosa cells surrounding the oocyte that 
extends into the center of the antral cavity22.  Call Exner Bodies develop in tandem with 
the antrum, however the role of these structures is unknown. 
Class 2 follicles proceed to Class 3 (0.4-0.9 mm in diameter) during the end of the 
luteal phase4,25 (Figure 1.2).  Transition into Class 3 is marked by an increase in follicle 
diameter due to an increase in the mitotic index of granulosa cells25.  Approximately 15 
days later, during the follicular phase of the following cycle, Class 3 follicles convert to 
Class 4 follicles (0.9-2.0 mm in diameter)4,25 (Figure 1.2).  Class 4 follicles convert to Class 5 
follicles (2.0-5.0 mm in diameter) ten days later during the late luteal phase4,25 (Figure 1.2).  
Transformation from Class 1 to Class 5 takes approximately two cycles in total. 
The role of gonadotropins in early follicular development remains controversial29.  
For example, Hodgen (1989) suggests that follicular development from primordial follicle 
to primary follicle is gonadotropin independent and subsequent development to a 
secondary follicle requires gonadotropins, whereas Fauser (1997) and Hillier (1994) suggest 
follicular growth to Class 2 occurs in the absence of gonadotropins.  Continual growth and 
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development of follicles to Class 5 is observed throughout life, including during conditions 
when endogenous gonadotropins are significantly decreased such as: pre-puberty, 
pregnancy, during OC use, and in women without gonadotropin secretion due to 
hypothalamic-pituitary failure or hypophysectomy, suggesting that follicles <2 mm in 
diameter require only basal levels of gonadotropins for growth and development10,20,21,30-35.  
Regardless of when follicles become dependent on gonadotropins, basal levels are required 
to sustain growth and development to Class 5.  Circulating levels of FSH are correlated to 
follicle quality of Class 5 follicles, therefore, it is suggested that follicles become dependent 
on cyclic changes when they reach Class 5 and remain dependent on cyclic gonadotropin 
changes until ovulation during Class 87,10.   
1.1.6 Exponential Growth Phase 
During the exponential growth phase the follicle progresses from Class 5 to Class 8 
(Figure 1.2).  This phase takes approximately 20 days, with each stage lasting five days25.   
The predominant events of the exponential growth phase include, but are not limited to, 
recruitment and selection of a dominant follicle followed by ovulation of a pre-ovulatory 
follicle7. 
1.1.7 Recruitment 
The term ‘recruitment’ is used throughout literature to define two separate events.  
“Initial recruitment” refers to the entry of primordial follicles into the growing phase and 
occurs continuously throughout reproductive life beginning during fetal development and 
continuing to menopause.  “Cyclic recruitment” refers to the process whereby a small 
cohort of antral follicles is rescued from atresia via FSH-induced growth.   Although both 
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definitions outline a process of recruitment, for the purposes of this review the term 
recruitment refers to “cyclic recruitment”. 
The demise of the corpus luteum during the late luteal phase results in remarkable 
changes within the ovary including, but not limited to, a decrease in progesterone, estradiol 
and inhibin A allowing for an increase in FSH approximately 12 days after the preceding 
midcycle LH surge10,36,37.  Follicle stimulating hormone must increase 10 to 30% above 
basal levels in order to rescue a cohort of 1 to 15 Class 5 follicles, at similar but not 
identical stages of development, from atresia10,26,38-41 (Table 1.1).  Although all follicles are 
suspected to have equal potential for maturation, only the follicles at advanced stages of 
development during the intercycle gonadotropin rise are recruited for further follicular 
development22.  Prolonged increases of FSH above threshold or extremely high levels of 
FSH result in higher than average numbers of follicles being recruited, such as during 
hyperstimulation protocols of IVF treatment22.  The FSH threshold varies between 
individuals, but appears to remain relatively constant within individuals. 
The recruited cohort is comprised of follicles that left the resting pool, by chance, 
at approximately similar times several months earlier22.   The best knowledge, to date, 
suggests that the continual entry of primordial follicles into the growth phase ensures a 
cohort of follicles are developmentally capable of responding to the intercycle increase in 
FSH10; however, the recent finding of follicular waves suggests that two to three cohorts of 
follicles are recruited at separate times during a single ovarian cycle42,43.  Recruitment of a 
cohort of follicles is preceded by an increase in FSH, suggesting that FSH plays a large role 
in follicle recruitment42.  Further research is needed to determine the exact physiologic 
mechanisms and biologic factors responsible for follicle recruitment in humans. 
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The largest follicles present at the beginning of the follicular phase possess the 
greatest number of FSH receptors, which in turn provides these follicles with a low FSH 
threshold38.  Large follicles have a competitive advantage over smaller follicles because 
large follicles can respond to lower levels of FSH earlier than smaller follicles.  Responses 
to increasing FSH include an increase in granulosa cell mitosis and glycosaminoglycan 
production (increases the volume of the antral cavity), induction of gene expression of  
granulosa cell FSH receptors and nonsteroidal  growth factors including the insulin like 
growth factor system, fibroblast growth factor, transforming growth factor-β, activin and 
the aromatase enzyme complex; however, this complex is not fully engaged until follicles 
exceed 10 mm in diameter10,44-46. 
1.1.8 Selection 
Selection is the process by which one follicle from the recruited cohort is 
physiologically “selected” to attain “dominance” and continue development to ovulation, 
with the remaining non-selected follicles of the cohort undergoing atresia.  The process of 
selection ensures the species specific ovulatory quota of follicles develop47.   Although 
humans develop two to three follicular waves per ovarian cycle, only the wave that initiates 
development during the late luteal phase typically produces one pre-ovulatory sized follicle 
resulting in subsequent ovulation42,43. 
Selection of the pre-ovulatory follicle from the cohort of recruited follicles occurs 
between days 5 to 7 of the menstrual cycle42.  However, the diameter at which selection 
occurs is debatable;  Gougeon (1989) suggested follicles are selected between 5.5 to 8.2 
mm in diameter (Class 6), Chikazawa et al. (1986) reported follicles are selected at 4.7 ± 0.2 
mm in diameter (Class 5); whereas, Macklon and Fauser, (1999) Pache et al., (1990) van 
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Santbrink et al., (1995) and Baerwald et al. (2003) suggested follicles are selected at 
approximately 10 mm in diameter (Class 6)7,29,43,46,48,49 (Table 1.1).  Follicle diameter at the 
beginning of the follicular phase ranges from 4 to 8 mm in diameter and few 
morphological differences are observed between follicles <8 mm.  Taken together, this 
data is interpreted to mean that follicle selection does not occur before follicles reach 8 mm 
in diameter50.   
At the time of selection, the selected follicle can be differentiated from the other 
healthy follicles of the cohort by it its larger size, higher mitotic index, detectable amounts 
of FSH and an appreciable amount of estrogen in the follicular fluid50,51.  Gougeon and 
Lefevre suggested that the largest follicle present at the beginning of the follicular phase is 
selected for dominance, because the selected follicle typically has the highest mitotic index 
of all follicles within the cohort, thus preventing smaller follicles from making up the 
growth delay50.  Once selected the follicle is defined as a “dominant” follicle and can be 
differentiated from the other follicles due to its larger size, morphology, increased secretion 
of estrogen and inhibin and complete induction of aromatase46,49,52-55.  The mechanisms 
responsible for selection of a single dominant follicle have not been fully elucidated; 
however, researchers suggest that decreasing levels of FSH in concert with increasing levels 
of estrogen are the primary regulators of selection56,57. 
1.1.9 Maturation of the Dominant Follicle Destined to Ovulate 
Once selected the dominant follicle continues increasing in size through 
accumulation of follicular fluid and proliferation of granulosa and theca cells until it 
reaches Class 7 (8-16 mm in diameter) followed by Class 8 (18-20 mm in diameter)10 
(Figure 1.1).  The dominant follicle undergoes its most profound transformation during the 
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last 10-15 days of development7.  The final two weeks of follicular growth are associated 
with a 12 mm increase in diameter7.  To put this into perspective, the follicle takes more 
than 330 days to reach 6 mm in diameter from initiation of growth but takes 10 days to 
increase its size by 12 mm in diameter. 
Soon after selection, the dominant follicle transforms from an androgen producing 
structure to an estrogen producing structure; therefore, the androgen:estrogen ratio of the 
follicular fluid decreases due to increased aromatase expression and subsequent estrogen 
production10.  Systemic estrogen levels begin increasing approximately five days before the 
mid-cycle gonadotropin surge42,58,59. Ultrasonographic visualization of the “dominant” 
follicle coincides with the initial increase in plasma estradiol concentrations49.   The 
majority of systemic estrogen present during the mid-to-late follicular phase is produced by 
the dominant follicle as demonstrated by dramatically elevated levels of estrogen in the 
venous effluent of the ovary containing the dominant follicle, and a significant correlation 
between increasing concentrations of serum estradiol and growth of the dominant 
follicle49,58. The increasing levels of estrogen synergistically act with FSH to further 
stimulate granulosa cell proliferation and stimulate the effects cAMP in an autocrine 
fashion44,60. 
Continued dominant follicle development is maintained by autocrine and paracrine 
growth factors that stimulate increased vasculature of the dominant follicle and FSH 
responsiveness, which allows the follicle to sustain growth and development in the face of 
waning levels of FSH61.  Further growth is supported via the expression of LH receptors 
during the mid-to-late follicular phase, at a time when LH concentrations begin to 
increase62,63.  Luteinizing hormone receptors are predominantly expressed on the mural 
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granulosa cells adjacent to the basal lamina, placing them in close proximity to the vascular 
supply of the theca interna63.  By day nine, the vasculature of the theca interna within the 
dominant follicle is two times that of any other follicle providing preferential delivery of 
gonadotropins to the newly formed LH receptors of the mural granulosa cells64.  Binding 
of FSH and LH to their respective receptors produces similar cellular responses since both 
receptors are coupled to a cAMP signaling system65.  Thus, increasing LH concentrations 
during the mid-follicular phase sustains dominant follicle growth and development by 
stimulating similar cellular pathways to that of FSH binding to FSH receptors.  
Furthermore, FSH and LH receptors have an additive affect when the receptors are not 
saturated, thus providing continued gonadotropin support in the face of declining FSH and 
increasing LH levels59.  Zeleznik suggests the decreased dependency of the dominant 
follicle on FSH may be the result of the acquisition of LH receptors on granulosa cells59. 
The dominant follicle is suggested to cause atresia of the subordinate follicles by 
one of two mechanism: (i) the dominant follicle secretes a factor that directly inhibits 
subordinate follicular growth and development or (ii) the dominant follicle indirectly causes 
atresia of the subordinate follicles though negative feedback mechanisms66. The dominant 
follicle produces increasing levels of estrogen and inhibins which suppresses FSH release 
from the anterior pituitary thus withdrawing the gonadotropin support needed to sustain 
follicular development of subordinate follicles36,67. The lack of gonadotropin support results 
in atresia of all but the dominant follicle61. 
Dominant follicle growth is associated with granulosa cell mitosis and antrum fluid 
accumulation26.  The theca layer undergoes increased vascularization and hypertrophy until 
ovulation7.  During Class 8 the basement membrane becomes less visible, mitosis of the 
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granulosa cells dramatically declines and the granulosa cells and their nuclei increase in 
diameter52. Upon reaching Class 8, the follicle is considered mature and will ovulate if 
stimulated by a gonadotropin surge; if a gonadotropin surge does not occur than the 
follicle regresses. 
1.1.10 Ovulation 
Ovulation begins at the time of the gonadotropin surge and involves local 
alterations in and around the 15 to 28 mm graafian follicle until the follicle ruptures 
releasing the fertilizable oocyte10,42,43,52,68.  The complex process of ovulation takes 
approximately 36 to 38 hours in humans and involves biochemical, morphological and 
physiological changes, all of which have not been completely elucidated68. 
The mid-cycle estradiol peak initiates organization of the granulosa cells, followed 
by disorganization of the granulosa layer during preluteinization of the follicle7,52. The onset 
of the mid-cycle gonadotropin surge stimulates the oocyte (which is arrested in dictyate 
stage of prophase I) to complete its first meiotic division and become arrested in   
prophase II as a secondary oocyte26.  An LH threshold must be reached and maintained for 
14 to 27 hours for full maturation of the oocyte to occur69.  Oocyte Maturation Inhibitor is 
suggested to inhibit oocyte maturation before the mid-cycle gonadotropin surge.  The mid-
cycle gonadotropin surge suppresses the action of oocyte maturation inhibitor, allowing 
meiosis to proceed to prophase II71.   The LH surge is terminated by negative feedback of 
progesterone and 17β-hydroxyprogesterone on the hypothalamo-pituitary-ovarian axis10,70.   
The midcycle gonadotropin surge also suppresses granulosa cell mitosis, stimulates 
large lacunae formation within the granulosa cells, stimulates a decrease in estrogen and 
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androgen concentrations in follicular fluid and stimulates granulosa cell lutienization as well 
as synthesis of prostaglandin E2 and F2α and other eicosanoids16,72.  The exact role of 
prostaglandin E2 and F2α is unknown71.  Further, the LH surge activates a number of 
intraovarian regulatory systems (Figure 1.3) that act synergistically to induce vascular 
changes and degrade the extracellular matrix through the dissociation of fibroblasts and 
collagen of the theca externa and tunica albuginea on the apex of the follicle68,68.  The 
vascular changes stabilize or increase the liquid pressure within the follicle to avoid collapse 
of the follicle when the follicle is leaking fluid followed by rupture73.  
Few morphological changes occur in the follicle wall until a few hours before 
ovulation74.  Hours before ovulation blood vessels from the theca interna invade the, once 
avascular, granulose layer.  Extra-vasiated blood cells are observed within the extracellular 
spaces around the fibroblasts75.  Follicular fluid volume increases immediately before 
ovulation without any significant changes in pressure70.  Minutes before follicular rupture, a 
stigma forms in the apical region of the follicle wall due to thinning of the collagen layers 
and degradation of the connective tissue elements. Immediately before follicle rupture, the 
surface epithelium becomes necrotic and sloughs off the apex of the follicle76. 
Ovulation is often likened to an inflammatory event due to the presence and involvement 
of inflammatory cells.  The LH surge stimulates the production of interleukin-1 and 
chemokines which attract leukocytes, neutrophils and macrophages to work together to aid 
in the degradation of the extra cellular matrix68. 
Two theories of ovulation - the pressure theory and the smooth muscle theory - 
predominated during the first half of the 20th century.  The pressure theory states an 
increase in intrafollicular pressure due to vasodilatation and ruptured blood vessels, 
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Figure 1.3: Overview of LH-induced pathways in the ovulatory cascade.  LH 
induces synthesis of mediators that promote either degradation of the 
extracellular matrix (ECM) and/or vascular changes (permeability 
increase, blood flow increase).  These changes lead to a decreased 
tensile strength and a positive intrafollicular pressure.  BK, Bradkinin; 
GRO, growth regulating onocogene; HI, histamine; IL, interleukin; 
LT , leukotriene; MCP, monocyte chemotactic protein; MMP, matrix 
metalloproteinase; NO, nitric oxide; P, progesterone: PA, 
plasminogen activator; PAF, platelet activating factor; PG, 
prostaglandin; VEGF, vascular endothelial growth factor. (from 
Branstrom, 2004). 
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increases in intrafollicular osmotic pressure and increases in follicular fluid volume cause 
follicular rupture77-79.  However, researchers have disproved the pressure theory by 
reporting that intrafollicular pressure does not increase during the few hours leading to 
ovulation but remains between 15 - 20 mm Hg76,80. 
The smooth muscle theory is defined as a contraction in smooth muscle contained 
in the follicular wall, inducing ovulation74.  In the early 1900's, researchers reported the 
presence of smooth muscle cells in the follicular wall, however the muscle could not be 
chemically or electrically stimulated to induce ovulation81,82.  In 1919, Corner suggested the 
“smooth muscle cells” of the follicle wall were actually long spindle-shaped fibroblasts 
enveloped in collagenous fibrils83.  Technological advances in polarization microscopy 
supported this report when Claesson revealed that the birefringence characteristic of 
muscle cells was not present in follicle walls but birefringence typical of connective tissue 
was84.  To date, there is no convincing evidence to suggest ovarian contractions are 
essential to ovulation.  However, rhythmic ovarian contractions are occasionally observed 
near the time of ovulation, suggesting smooth muscle contractions may play a role in 
ovulation74. 
The proteolytic enzyme theory is the currently accepted theory for the mechanism 
of ovulation74.  This theory states that a small portion of the follicular wall, known as the 
apex, is digested by enzymes until the distensibility of the wall decreases to the point that it 
can no longer sustain the constant intrafollicular pressure of 15 to 20 mm Hg, resulting in 
rupture of the follicular wall to release the mature oocyte.  Progesterone, FSH and LH 
induce synthesis of mediators and activate proteolytic enzymes in an orderly sequence to 
digest the collagen within the follicle wall and to decrease the distensibility of the apex 
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(Figure 1.3)85.  Granulosa and theca interna cells produce plasminogen activator in 
response to the mid-cycle gonadotropin surge.  Plaminogen activator activates plasminogen 
to plasmin, in the follicular fluid.  Plasmin subsequently generates collagenases which digest 
collagen at the apex of the follicular wall70.  The changes that occur at the ovulatory site 
have been described as a pathophysiological process because the dense collagen layer of the 
tunica albuginea and theca externa is disrupted86.  Once the stigma of the follicular wall 
ruptures, the follicular fluid and oocyte evacuate the antral cavity. 
1.1.11 Duration of Human Folliculogenesis 
Follicular development from primordial follicle to ovulation takes approximately 12 
menstrual cycles26 (Figure 1.1).  Initially, follicular development is a slow process.  It is 
estimated that a primordial follicle takes > 150 days to develop into a primary follicle and 
>120 days for the transition from the primary to secondary stage of follicle development26.  
The speed at which follicles progress through each stage of development increases 
dramatically once the secondary follicle develops.  It takes 65 days for a secondary follicle 
to progress to Class 5 , five more days are needed for selection to occur, followed by 15 
days of maturation to the pre-ovulatory sized follicle10.  Gougeon suggested that follicular 
development from Class 1 (pre-antral) to Class 8 (pre-ovulatory) takes approximately 85 
days10 (Figure 1.2).   
1.1.12 Summary 
The knowledge of the basic biology and physiologic processes underlying 
reproductive function, in women, has grown exponentially since de Graaf defined the 
ovarian follicle and oocyte87.  However, we do not yet completely understand the 
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complexity, and intricacies of the ovary and ovarian follicle.  New dynamic, 
interdisciplinary research techniques are providing researchers the tools to uncover the 
mysteries of reproductive organs in women.  For example, follicular wave development 
was recently documented in humans42,43.  Further research is needed to determine the 
physiologic and endocrine processes responsible for initiation and maintenance of waves.  
New research findings regarding the biology and physiologic mechanisms associated with 
reproductive functioning will allow us to develop safer, more efficacious hormonal 
contraception and infertility treatments. 
1.2 Ultrasonographic Imaging of the Ovaries and Uterus 
1.2.1 Overview of Ultrasound Imaging 
The introduction of gray-scale ultrasonography has revolutionized how clinicians 
and researchers examine ovarian follicular development.  Before the introduction of 
ultrasonography, tissue samples were examined using histological techniques that are time 
consuming and result in destruction of the tissue as well as only providing information 
about a single point in time.  Further, histological studies are ethically difficult in live 
humans.  Ultrasound provides a direct, non-invasive and atraumatic tool to observe the 
dramatic morphological changes that occur within the reproductive organs without 
interfering with the physiological processes of these organs while minimizing discomfort to 
the individual88,89. Further ultrasound can be used to detect minute differences in 
morphology and physiologic state or reproductive organs thus eliminating the need for 
surgery90. 
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Ultrasonography is based on the ability of tissue structures to reflect high frequency 
sound waves91,92.  The ultrasound machine is composed of a transducer, a computer 
processor and a monitor screen.  The transducer contains piezoelectric crystals that expand 
and contract to produce a high frequency sound wave when stimulated by an electrical 
current.  The sound wave propagates into the tissue until it is reflected back towards the 
transducer after collision with a tissue interface.  The degree of wave reflection is 
associated with tissue density and is represented by shades of gray ranging from black to 
white.  Dense structures (e.g. cervix) reflect the majority of sound waves and therefore 
appear white or hyperechoic whereas fluid-filled structures appear black or hypoechoic 
because they propagate sound waves93.  Waves which are not reflected back to the 
transducer are scattered, refracted or absorbed into the tissue91.  The reflected sound wave 
returns to the piezoelectric crystal within the transducer causing the piezoelectric crystal to 
compress followed by the subsequent generation of an electrical signal.  The electric signal 
is processed for display in the receiver and then stored as binary digits or “bits” in a digital 
scan converter.  
Ultrasound images are produced when the stored information from the digital scan 
converter is converted to an electrical signal.  The electrical signal causes an electron gun to 
expel an electron beam onto a phosphor screen resulting in the emission of light.  The 
horizontal movement of the electron beam forms raster lines.  Vertical scanning lines are 
subsequently produced when the electron beam of the raster line turns on and off91.   The 
intersection of a vertical scanning line with a raster line produces a pixel.  Each pixel 
represents a discrete tissue reflector.  Pixel brightness is displayed as one of 256 shades of 
grey (black = 0 and white = 255) and is related to the amplitude of the reflected signal or 
tissue density91.  Currently, ultrasound machines usually display images of 480 x 640 pixels.  
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Each ultrasound image is created by the processing and displaying of numerous sound 
beams which have been focused to increase lateral resolution and optimize viewing92. 
The primary reason for performing transvaginal ultrasound is to monitor ovarian 
follicular maturation and ovulation during natural menstrual cycles and controlled ovarian 
hypserstimulation and ovulation induction during infertility treatments93.  Current infertility 
investigations utilize transvaginal ultrasonography to track ovarian follicular development 
and ovulation, aid in invasive ultrasound guided procedures, detect early pregnancy, 
examine pathologies and assess the uterus and ovaries for anomalies such as cysts, tumors, 
fibroids and endometriomas90.  The uterus and ovaries are easily examined using B-mode 
(brightness mode) transvaginal ultrasound, particularly due to the close proximity of the 
organs to the transducer during ultrasound examination.   
1.2.2 Ultrasonographic Characteristics of the Ovaries 
The ovaries are visualized as a pair of almond shaped structures (3 cm x 2 cm x 1 
cm) that lie on either side of the uterus93.  They are typically located posterior to the broad 
ligament, anterior to the iliac vessels and ureters and inferior to the uterine tube93.  The 
ovaries are secured in the peritoneal space by the ovarian and suspensory ligaments93.  Each 
ovary is supplied with blood by an ovarian branch of the adnexal branch of the uterine 
artery93.  Ovaries have a coarse low-level echo pattern which is interspersed with anechoic 
areas representing ovarian follicles, cysts or corpora lutea93.  Mature ovarian follicles 
measure approximately 20 to 24 mm in diameter93.  Ovarian follicles appear as round 
anechoic spheres surrounded by a thin hyperechoic follicle wall93.   
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Morphological changes associated with impending ovulation can easily be detected 
using two-dimensional transvaginal ultrasonography.  The cumulus-oophorus expands and 
can be observed in up to 80% of follicles 12 to 24 hours before ovulation89.  The apex of 
the follicle wall thins and the deep internal portion of the follicle wall thickens beginning 
approximately three hours before ovulation88.  The follicle wall becomes less echoic (i.e., 
darker) as the tissue layer expands and becomes loosely organized and vascularization 
increases in preparation for ovulation88.  The increased vascularization can be visualized 
using Doppler ultrasonography93.  The follicle flattens out or becomes irregularly shaped in 
association with expansion and crenelation of the follicle wall88.  Approximately 15 to 20 
minutes before ovulation a stigma forms at the follicular apex followed by the rupture of 
the follicle and the rapid release of approximately 50% of the follicular fluid within 15 
seconds89,3.  Complete evacuation of follicular fluid ranges from six seconds to >18 
minutes in follicles that completely expel their follicular fluid89.  The point of follicular 
rupture can be observed for up to a week following ovulation90. 
Corpora lutea are observed in the ovarian location where the follicle was formerly 
observed immediately following follicle collapse using transvaginal ultrasonography89,94,95.  
The wall of the corpus luteum becomes highly vascularized and thickens and folds during 
lutienization94.  The corpus luteum is typically described as having mid-range 
echogenicity96; the outer surface (i.e., luteal wall) has a more echogenic echotexture than the 
relatively hypoechogenic central portion which is either cystic (i.e., hypoechoic) or solid 
(i.e., hyperechoic) in structure94.   Approximately 60% of women hemorrhage into the 
developing corpus luteum following ovulation resulting in the formation of a corpus 
hemorrhagicum97.  If pregnancy does not occur, the corpus luteum begins to regress two to 
five days before the following menstrual period begins94.  Regression of the corpus luteum 
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involves a decrease in cell size and degenerative changes in the nuclei of luteinized cells as 
well as fatty degeneration94.  The vascular supply decreases and fibrosis is observed94.  The 
cells of the corpus luteum ultimately degenerate into a amorphous hyaline mass, held 
together by strands of connective tissue; this structure is defined as a corpus albicans94.  
Complete regression of the corpus albicans occurs over the following few menstrual 
cycles94 
Ovulatory failure can result in the formation of ovarian cysts, luteinized unruptured 
follicles and hemorrhagic anovulatory follicles90.  Anovulatory follicles posses characteristic 
echotexture that can be used to assess follicular health.  Anovulatory follicles generally have 
thin highly echoic (i.e., bright), clearly demarcated follicular walls of uniform thickness with 
an echotexture that is characteristic of a cohesive tissue layer88.  However, echoic structures 
protruding into the antral cavity as well as free floating in the antral cavity are commonly 
observed90.  The increased gray-scale values of the follicular wall may be associated with 
decreases in vascularity88.  The cumulus-oocyte complex is not evident in anovulatory 
follicles88.  Anovulatory follicles do not form a stigma nor do they change shape88.  These 
follicles generally develop past normal ovulatory diameter (i.e., >25 mm) remain static for 
one to several days and then regress without lutienization90.  Luteinized unruptured follicles 
generally have thick follicular walls with hazy indistinct borders between the antrum/wall 
interface.  These follicle walls have similar echotexture to luteinized tissue90.  Luteinized 
unruptured follicles typically regress in a similar time period to normal corpus luteum 
regression90.  Hemorrhagic anovulatory follicles are characterized by hemorrhage into the 
antral cavity followed by the formation of fibrin network within the antrum90.    
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1.2.3 Ultrasonographic Characteristics of the Uterus 
The uterus is a pear-shaped, hollow, muscular organ with thick walls and an 
average length of 7.5 cm, a depth of 2.5 cm and a width of 5 cm at its widest point93.  The 
uterus lies posterior to the urinary bladder and anterior to the rectum and has a 
homogenous echotexture with echoes of medium intensity90,93.  The uterine cavity appears 
as a transverse slit in sagittal section and a triangle in transverse section with the opposing 
layers of the endometrium appearing as an echogenic line in the central uterine cavity93.  
The echotexture of the endometrium varies throughout the menstrual cycle and is related 
to the circulating concentrations of estrogen and progesterone90.  The echotexture of the 
myometrium does not change during the menstrual cycle90.  
1.2.4 Computer Assisted Image Analysis 
Currently, researchers are developing new techniques to evaluate ultrasound image 
attributes to elucidate the physiologic status of ovarian follicles and corpora lutea with a 
single non-invasive ultrasound exam98.  The development of non-invasive techniques will 
result in immediate improvement in the clinical management of infertility patients98. 
Each ultrasound image is composed of thousands of discrete picture elements or 
pixels99.  The human eye can perceive smooth transitions in shades of gray, but can only 
distinguish between 18 to 20 shades of gray, therefore, most of the gray-scale information 
contained within an ultrasound image can not be evaluated by the human eye100.  
Ultrasound image analysis overcomes subjective human evaluation of ultrasound images by 
using a series of processing steps and complex computer algorithms to quantify 
echotextural characteristics within the image98.  The image attributes can then be correlated 
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to physiologic status of ovarian structures.  The validity of the image analysis technique has 
been verified through correlation of ultrasound image attributes with histologic attributes 
in animal models101-103.  The ultimate goal of image analysis techniques is to provide 
clinicians and researchers with a tool to assess the physiology underlying ovarian follicular 
growth and development with a single ultrasound exam99. 
Three image attributes are typically quantified during analysis.  These include, but 
are not limited to: (i) numerical pixel value (NPV) defined as the mean pixel gray-scale 
value of the sampled pixels, (ii) pixel heterogeneity (PH) defined as the standard deviation 
of the mean gray-scale values of the sampled pixels, and (iii) the area under the curve 
(AUC) defined as the total sum of the gray-scale values within the sampled area.  Spot 
metering, linear and time-series analyses, and regional surface analyses are techniques 
utilized to sample ultrasound image attributes of ovarian structures98,99.  Caution must be 
taken when performing all analyses to avoid placing sampling lines on image artifacts (e.g., 
enhanced through transmission, shadowing, specular echoes, refraction and beam width 
artifacts) that may falsely increase or decrease image attribute values resulting in inaccurate 
interpretation of the physiologic status of the ovarian structure. 
1.2.5 Spot Metering 
The simplest imaging technique utilizes a small circle to isolate and quantify pixels 
in an area of interest98, 99.  The computer program determines the precise gray-scale value of 
the pixels within the sample area and provides output in the form of image attributes such 
as NPV, PH and AUC.  This technique is used to compare different areas within the same 
follicle or the same area of the follicle at different time points98, 99.  For example portions of 
the follicle wall or corpus luteum may be quantified to evaluate characteristics of follicular 
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growth and regression, impending ovulation, atresia and luteal development and 
regression98,99,101-105. 
1.2.6 Line and Time Series Analysis 
A computer-generated line (one or more pixels wide) is drawn across a desired 
region of the follicle or luteal structure98,99.  The intensity of each pixel within the line are 
displayed in a graphical format comparing distance versus pixel value98,99.  This technique is 
commonly used to observe changes in the follicle wall of a single follicle or many follicles 
over time101,106.  To increase the precision and accuracy of analysis image attributes of many 
lines at different locations of the follicle wall can be averaged to obtain a single image 
attribute.   
Time series analysis of the same follicle may be done by concatenating individual 
linear pixel intensity graphs into a single image98,99.  The composite image undergoes 
shading algorithms to provide a three-dimensional graph which compares follicle diameter, 
pixel intensity and time98.  Evaluation of the surface features can provide clues regarding 
the physiologic health of the follicle.  Echotexture of the follicular wall and antrum can be 
assessed as the follicle progresses through different stages of growth and regression99.  
1.2.7 Region Analysis 
Region analysis is the most promising technique to evaluate the physiological status 
of a follicle98.  This technique involves overlaying a pixel-by-pixel mesh onto a selected 
region of the follicle to produce a three-dimensional image98,99.  A computer-generated skin 
can be placed on top of the mesh framework to provide a topographical image.  The image 
can be further enhanced by applying shading algorithms to the topographical image.  
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Shading highlights detail and enhances perception of surface features such as texture or the 
portion of the image comprised of echo intensities of interest.  Region analysis may 
develop into a clinical tool to instantly assess ultrasound image attributes associated with 
the health and viability of a follicle. 
1.3 Ovarian Follicular Development during Oral Contraceptive Use 
1.3.1 The Introduction of Oral Contraceptives 
Contraceptive choices radically changed for women in 1957, when the Food and 
Drug Administration approved the first menstrual regulator, Enovid™, which contained 
synthetic estrogen (150 µg mestranol) and synthetic progestin (9.85 mg norethynodrel)107.  
Enovid™ was initially introduced as a menstrual regulator to navigate around secular and 
religious tenets against the use of birth control.  Interestingly, Enovid’s™ packaging 
initially carried a warning that it induced contraceptive properties including, but not limited 
to, inhibition of ovulation108.  Soon after Enovid™ was introduced, the number of women 
experiencing menstrual irregularities and disorders dramatically increased, likely due to the 
fact that the only legal method of obtaining birth control in many American States was 
under the guise of menstrual irregularities108.  In 1960, the Food and Drug Administration 
approved Enovid™ as an oral contraceptive.  The effects Enovid™ had on ovarian 
function were not completely known.  However, it was hypothesized that administration of 
synthetic progestin created a pseudo-pregnancy that prevented ovulation while the estrogen 
component provided cycle control to reduce unscheduled bleeding. 
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1.3.2 Characteristics of Oral Contraceptives 
Prior to 1960, non-steroidal contraceptives were the only available contraception to 
prevent pregnancy.  The introduction of Enovid™, revolutionized contraceptive use by 
providing women with more contraceptive choices.  Today, OC are the most commonly 
used, reversible contraceptive in the world109.   Combined OC have evolved to include 
different progestins with lower androgenic activity and mestranol has been replaced with 
EE; thus, virtually all currently used OC combine ≤35 µg EE with a synthetic progestin110.  
The progestin component of combined OC is thought to directly affect ovarian function, 
suppress the mid-cycle LH surge and subsequent ovulation, decrease the permeability of 
the cervical mucus and endometrial receptivity for embryo implantation, and decrease tubal 
and uterine motility causing a delay in gamete transport111.  The estrogen component is 
postulated to directly affect the ovary, suppress FSH release, inhibit ovulation and provide 
endometrial stability leading to predictable bleeding patterns.  The extent of pituitary-
ovarian suppression appears to be related to the dose of EE111.  For example, OC 
containing ≥30 µg EE suppress follicular development better than an OC containing 20 µg 
EE.  Further research is required to determine the exact mechanisms of action that 
estrogen and progestin have on the reproductive organs during OC use.  Progestin-only 
OC are also available as a contraceptive choice.  However, progestin-only OC have lower 
efficacy than combined OC so they are typically used for special cases, particularly in 
lactating women or women with sensitivity to EE.  
Conventional OC administration consists of a 28 day cycle comprised of 21 daily 
active pills followed by a 7 day hormone free interval (HFI).  This 28-day administration 
scheme was implemented to mimic the physiological event of monthly menstruation and 
 32
provides only the illusion of natural menstrual cyclicity.  The purpose of inducing a 
menstrual bleed during OC use was to increase the acceptability of OC even though it has 
no reported physiologic benefit.  Currently, researchers are examining the efficacy, 
acceptability and physiologic effects of replacing the HFI with seven daily active pills, in a 
continuous dosing scheme112-132.   
Oral contraceptives are generally prescribed in one of three dosing fashions:         
(i) monophasic, wherein each active pill contains the same concentration of steroids;        
(ii) biphasic and (iii) triphasic, changes in estrogen concentration are dependent on the OC 
type wherein the concentration of progestin increases by one (biphasic), or two (triphasic), 
increments as the cycle progresses from Day 1 to 28. 
1.3.3 Follicular Development during Oral Contraceptive Use 
Twenty-one studies were reviewed to determine the effect of administering 20 to 
40 µg of exogenous EE in combination with various progestins on the hypothalamo-
pituitary-ovarian axis112,133-148,149,152-154.  Follicular development ≥10 mm in diameter was 
observed in all 17 studies, which utilized ultrasound to examine follicular diameter during 
OC    use112,133-148.  Follicular development ≥ 10 mm increases the chances of “escape” 
ovulation during OC use, since follicles are physiologically selected at 10 mm for 
preferential growth and ovulation during natural cycles149.  The high incidence of dominant 
follicle development during compliant OC use, in conjunction with the report of OC 
failure rates ranging from 16-40% in subgroups of women attending family planning 
clinics, suggests that the current conventional OC dosing schemes do not completely 
suppress follicular development and should be improved to decrease the current “real-life” 
failure rates150,151.  Furthermore, 15 of the 21 studies reviewed reported follicular 
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development to ostensibly ovulatory diameter133,134,136,137,139-144,147,148,152-154.  Eight of the 21 
studies observed ovulation during compliant OC use135,139,142,144,146,148,153,154.  No pregnancies 
were reported; however, only 3 of the 8 studies reported pregnancy rates.  Follicles which 
develop to pre-ovulatory diameter during OC use likely do not ovulate due to suppression 
of the mid-cycle gonadotropin surge or the inability of the follicle to respond to LH due to 
the effects of progesterone on the population or sensitivity of LH receptors133.  The 
variable ovulatory ability of follicles during compliant OC use can not yet be explained.  
Further studies examining changes in gonadotropins, in the presence of an ovulatory-sized 
follicle, as well as morphological changes of pre-ovulatory sized follicles may help to 
elucidate some of the mechanisms associated with ovulation during compliant OC use.  
Most dominant follicles which developed to pre-ovulatory diameter during 
compliant OC use regressed133,134,139-141,143,144,148.  However, some follicles develop to pre-
ovulatory diameter in association with pre-ovulatory levels of estrogen133,146.  Further, 
follicles which develop to ovulatory diameter have similar ultrasound image attributes and 
are ultrasonographically indistinguishable from comparable natural-cycle follicles155,156.  
Similarities in ultrasound image attributes between natural cycle follicles and follicles which 
develop under the suppressive effect of OC can be interpreted to mean that follicles which 
develop during OC use have similar physiologic status to natural cycle follicles; hence, 
ovulations can occur resulting in pregnancy and OC failure. 
1.3.4 Follicular Development during the Hormone Free Interval 
Conventional OC regimens provide a seven day HFI to induce a withdrawal bleed 
during each 28-day cycle and decrease exposure to exogenous hormones.  Numerous 
studies have reported dominant follicle development during the HFI133,140,147,156-158 with a 
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number of these follicles continuing development to pre-ovulatory diameter133,140,158.  Over 
85% of dominant follicle development is initiated during the HFI133 and ovulation of up to 
50% of pre-ovulatory sized follicles has been reported158.   Ultra low dose OC (≤20 µg EE) 
appear to increase the risk of dominant follicle development during the HFI133,147.  
The seven day absence of exogenous hormones allows pituitary-ovarian activity to 
recover to levels observed during the early follicular phase of the natural menstrual cycle, 
particularly during administration of ultra-low dose OC133,145,156,157,159-164.  Follicle-stimulating 
hormone often rises above the threshold for ovarian stimulation during the HFI, allowing 
for gonadotropin-dependent follicular growth133,156,160,164.  Initiation of active dosing pills 
following the HFI causes a decrease in FSH regardless of the presence of a dominant 
follicle111.  If a dominant follicle is not present after initiation of active dosing pills, then 
folliculogenesis is completely suppressed.  If a dominant follicle is present, then follicle 
growth usually continues after initiation of the OC strip due to the decreased dependence 
of dominant follicles on gonadotropins160,164.  In the presence of an ovulatory sized follicle 
contraceptive efficacy is dependent on inhibition of the pre-ovulatory LH surge and the 
secondary contraceptive benefits of OC, which include, decreased permeability of the 
cervical mucous to suppress the entry of spermatozoa into the uterus, decreased 
endometrial receptivity for embryo implantation, and tubal and uterine motility causing a 
delay in gamete transport109.  
Decreasing the duration of the HFI or replacing some hormone-free days with 
administration of EE suppresses follicular development better than conventional dosing 
schemes126,142,145,147,165.  For example, decreasing the length of the HFI to four or five days 
during ultra low dose (≤20 µg EE) OC administration decreases ovarian activity and 
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estradiol levels better than conventional dosing schemes145,147,165.  Similarly, replacing the 
last five inert pills during the HFI with pills containing 10 µg EE reduces follicular growth 
compared to the conventional OC dosing scheme126,142.   Taken together, these findings are 
interpreted to mean that shortening or omitting the HFI would prevent a rebound in 
gonadotropins and increase contraceptive efficacy by decreasing the risk of dominant 
follicle development and subsequent contraceptive failure. 
1.3.5 Follicular Development after Prolongation of the Hormone Free Interval 
Prolonging the HFI through missed OC doses increases the risk of “escape” 
ovulation compared to doses missed during mid-cycle157,161-163,166,167.  Prolongation of the 
HFI provides more than seven days of unsuppressed follicular development.  The longer 
the HFI is extended past seven days, the greater the risk of pre-ovulatory follicular 
development.  For example, estradiol levels continue increasing if the HFI is extended to 
11 days120,157.  In addition, mean estradiol concentrations continue to increase, or remain 
static after reinitiation of OC following a ten day HFI, compared to a decrease in estradiol 
levels once OC are initiated after the seven day HFI157.  It is suggested that extending the 
HFI past seven days increases the number of dominant follicles (≥10 mm in diameter) that 
develop, as reflected by the higher estradiol levels following a ten day HFI157.  Prolongation 
of the HFI likely increases the risk of “escape” ovulation and subsequent conception due 
to increased dominant follicle development in combination with reduced secondary 
contraceptive benefits.  
Ovulation was observed in five of the ten studies which examined follicular 
development following prolongation of the HFI, however, no pregnancies were 
reported120,162,163,168,169.  Follicles which develop to ≥18 mm in diameter, after the extension 
 36
of the HFI, are probably capable of ovulation because these follicles can be induced to 
ovulate when stimulated with human Chorionic Gonadotropin170. 
1.3.6 Follicular Development after Missed Doses 
The risk of “escape” ovulation after missing doses of OC is largely dependent on 
the number of consecutive doses missed, the stage of the cycle where the OC were missed 
and the type of progestin contained in the OC.  Pituitary-ovarian suppression increases 
with the number of consecutive OC taken with maximum suppression typically occurring 
at the end of a 21-day OC cycle, although seven consecutive days of OC administration can 
adequately suppress ovarian activity168.  Differences in the type of progestins and their 
associated half-life can affect the number of consecutive doses that may be missed before 
the risk of “escape” ovulation increases.  Oral contraceptives comprised of progestins with 
longer half-lives appear to better maintain contraceptive properties following a higher 
number of consecutive missed doses than progestins with shorter half lives.  For example, 
an OC containing levonogestrel, which has a relatively long half life of 29 hours, maintains 
contraceptive efficacy for four days of consecutive missed doses, compared to an OC 
containing desogestrel, which has a half life of 16 hours, and can maintain contraceptive 
efficacy for only two consecutive missed doses166-169,171-174 . 
Differences between “escape” ovulation rates following missed dosing may also be 
due to individual variation in the effect the OC has on the hypothalamo-pituitary-ovarian 
negative feedback system.  It is important to note that the small sample size of the above 
studies may not have included individuals with greater susceptibility to “escape” ovulation; 
therefore, large-scale studies would be required to estimate the incidence of “escape” 
ovulation in association with the timing and number of missed OC doses. Up to 74% of 
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women report omitting ≥ 1 OC during each cycle175-178.  The high omission rate in 
combination with OC failure following missed doses, particularly missed doses that 
prolong the HFI suggest that a more efficacious OC should be developed that is capable of 
maintaining high efficacy following missed OC doses.  
1.3.7 Follicular Development during “Sunday Start” Initiation Schemes 
“Sunday Start” initiation schemes prolong the initiation of OC to the first Sunday 
during menses, compared to immediate start initiation schemes which administer OC on 
Day 1 of menses.  “Sunday Start” schemes were designed to increase user acceptability by 
suppressing menstruation during weekends when most sexual activity is presumed to 
occur.  Physiologically dominant follicles (≥ 10 mm) are commonly observed during the 
first seven days of the natural menstrual cycle149.  Utilization of “Sunday Start” regimens 
can increase the chances of OC failure because follicles can attain dominance during the 
HFI and continue developing to pre-ovulatory diameter once active OC are re-initiated, up 
to one week after the onset of menses133,144,156.  The risk of follicle development, ovulation 
and pregnancy in women using “Sunday Start” regimens has not been thoroughly 
examined. 
 
1.3.8 Follicular Development during Three Different Regimens of Oral 
         Contraceptive use 
 Schlaff et al., are the only group to date to use ultrasonography to examine ovarian 
follicular and endometrial development during continuous dosing schemes126.  This study 
examined ovarian follicular development ≥8 mm in diameter with transvaginal 
ultrasonography during the use of three different OC dosing schemes: (i) 21 days of 20 µg 
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EE + 100 µg levonorgestrel followed by seven days of inert pills, (ii) 20 µg EE + 150 µg 
desogestrel followed by two days of placebo then 10 µg EE for five days, (iii) 28 days of 20 
µg EE + 150 µg desogestrel for two 28 day cycles.  The results of the study were 
interpreted to mean, that continuous OC use provided greatest follicular suppression, in 
both the number and size, of follicles developing ≥ 8 mm in diameter.  The conventional 
group provided the least amount of suppression, in both follicle number and size, and the 
conventional dosing scheme with estrogen added to the HFI provided intermediate 
suppression of follicle number and size.  The findings of this study further reinforce the 
idea of shortening or omitting the HFI to suppress follicular development past the 
physiological stage of selection. 
1.3.9 Inhibiting Menstruation 
 Many clinicians, researchers and anthropologists propose that monthly 
menstruation is unnecessary and actually increases health risks to women179.  Thomas and 
Ellertson suggest that monthly menstruation is not the historical norm132.  For example, 
primitive women menstruated 66% less than the typical modern-day woman.  The increase 
in menstrual frequency in modern women is suggested to be due to evolutionary 
progression resulting in an earlier onset of menarche, later age of first birth, fewer 
pregnancies, shorter periods of lactation and a later onset of menopause in modern women 
compared to primitive women119.  Eaton et al., reported that late menarche, high parity, 
early age at first birth and early age at menopause are protective characteristics for breast 
and gynecologic cancers180.  It would then follow that suppressing menstruation would also 
provide women with protection from these cancers180.    
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 Inhibiting menstruation reduces undesirable menstrual-related symptoms which are 
reported to be the most common gynecologic complaint in American women aged 18 to 
50 years181.  Undesirable menstrual symptoms include dysmenorrhea, headache, migraine, 
asthma, premenstrual syndrome, acne and anemia131.  Thirty one percent of American 
women report spending approximately 10 days annually in bed due to menstrual 
morbidity181.  Menstrual morbidity also affects society as a whole.  Menstrual disorders 
decrease productivity by 25%, and are estimated to cost eight percent of the total wage bill 
in the United States132.  Thomas and Ellertson adequately summarized the status of 
menstrual related disturbances in today’s modern industrialized society when they stated, 
“there can be no other disease or condition that affects so many people on such a regular 
basis with consequences at both the societal and individual level, which is not prioritized in 
some way by health professionals or policy makers”132. 
1.3.10 Women’s Attitudes towards Inhibiting Menstruation 
 Most women in industrialized nations prefer to have a menstrual period with a 
frequency of every three months or not at all116,182,183.  Women’s attitudes toward inhibiting 
menstruation are culture-dependent.  Glasier et al. reported women’s acceptability to 
inhibiting menstruation varied depending on their country of residence183.  For example, 
6% of women living in Hong Kong compared to 37% of Scottish women prefer to be 
amenorrheic183.  Whereas 15-41% of women from Germany, Denmark and Australia prefer 
to inhibit menstruation116,125,184.  Common findings between the studies reviewed were:      
(i) that most women do not like menstruation, but (ii) less than half of women would 
actively inhibit menstruation.  Menstrual related adverse events were the most commonly 
reported reason for disliking menstruation.  The reported adverse events associated with 
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menstruation included: inconvenience, menstrual related symptoms, fatigue, acne, 
premenstrual syndrome, headaches and migraines130,183.  Women who preferred monthly 
menstrual cycles falsely believed that monthly menstruation was “natural” and ensured 
them that they remained fertile but were not pregnant125,183.  Women who have experienced 
amenorrhea, during continuous OC dosing, reported fewer menstrual complaints, better 
hygiene, higher quality of life and less blood loss122,124,182.   
 Ten percent to 65% of women stated optimal bleeding frequency would be every 
three months if they could use OC to control their menstrual frequency116,125,183,184.  
Curiously, the majority of women who actually participated in studies designed to evaluate 
continuous OC dosing schemes on ovarian function and patient acceptability preferred to 
continue with the continuous regimen after study completion112,123.  It appears that women 
are initially reluctant to initiate continuous dosing schemes but once initiated they prefer 
continuous OC administration to conventional dosing schemes. 
1.3.11 Non-contraceptive Benefits of Oral Contraceptives 
 Oral contraceptives were initially marketed for the treatment of menstrual 
disturbances.  Ironically, this therapeutic use does not appear in Food and Drug 
Administration approved labeling for currently marketed OC185.  Oral contraceptives are 
commonly prescribed to provide beneficial health benefits and to treat a variety of 
gynecologic disorders in addition to preventing pregnancy.  The health benefits of OC 
include: (i) providing 99% effective contraception, (ii) treating a number of gynecologic 
symptoms and (iii) preventing some gynecologic and other medical conditions186.  
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 Oral contraceptives protect women from primary and secondary dysmenorrhea and 
menorrhageia, menstrual cycle irregularities, iron deficient anemia, ectopic pregnancy, 
perimenstrual migraines, menses-related epilepsy and pregnancy related complications109,185.  
Oral contraceptives appear to aid in the prevention of osteopenia and may be used to 
manage a number of gynecologic disorders including dysfunctional uterine bleeding, 
persistent anovulation, premature ovarian failure, functional ovarian cysts, and pelvic 
pain109,185. 
 Long term OC use decreases the risk of developing uterine fibroids, endometriosis, 
recurrent ovarian cysts and acute Pelvic Inflammatory Disease by 50-70%109.   Long-term 
OC use also helps to protect women from iron deficient anemia, benign breast lumps, 
toxic shock syndrome, premenstrual syndrome, breast cancer, endometrial cancer and 
ovarian cancer, acne and hirsuitism187. 
 A number of OC protective benefits increase with increasing duration of OC use.    
Results from a recent large-scale study which examined the risk of reproductive cancers in 
OC users were interpreted to mean, that a history of OC use significantly reduced the risk 
of gynecologic cancers with the risk decreasing with increased duration of OC use188.  For 
example, the risk of ovarian cancer decreases by 40% after four years of OC use, 54% after 
eight years and 60% after 12 years189.  Similarly, the risk of endometrial adenocarcinoma 
decreases by 56% after four years of OC use, 67% after eight years and 72% after 12 
years190.  The protective benefits of OC against ovarian and endometrial cancer can persist 
for up to 20 years after discontinuation of OC use191-194. 
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1.3.12 Return to Fertility following Discontinuation of Oral Contraceptives 
 Oral contraceptives are one of the only forms of contraception that inhibit 
ovulation by physiologically suppressing the hormonal cues required for follicular 
development and ovulation.  Furthermore, OC are the contraceptive of choice for women 
in most industrialized nations109.  Therefore, it is essential to determine any residual effects 
OC may have on reproductive function once they are discontinued.  Differences in study 
design and population demographics among studies make it difficult to compare the return 
to fertility following discontinuation of OC. However, it is apparent that previous OC use 
temporarily delays conception, but does not permanently affect fertility.  A two to three 
month delay in conception following discontinuation of OC is commonly observed 
compared to discontinuation of non-hormonal contraception (i.e., intrauterine device, 
diaphragm, condom)195-204.  In contrast, a single study conducted in Malaysian women 
reported no difference between conception rates of women discontinuing hormonal or 
non-hormonal contraception205.    
 Researchers report that approximately half of all women (39%-56%) conceive 
within three months of discontinuing OC compared to almost two-thirds (54% - 65%) for 
previous users of intrauterine devices, diaphragms, condoms and “other” contraceptive 
methods200,205,206.  Furthermore, conception rates are similar two years after discontinuation 
of OC compared to discontinuation of non-hormonal contraceptives (90-99% versus 98%, 
respectively)200,201,203,205.  Conception rates following discontinuation of contraceptives, both 
hormonal and non-hormonal, should be compared to conception rates during natural 
cycles to determine the true residual effect contraceptives have on the return to fertility.  
For example, during natural cycles approximately 57% of women conceive within one 
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month of unprotected intercourse, 72% within six months, 85% within one year and 93% 
within two years207.  It appears that conception rates return to normal expected values 
within two years of discontinuing contraception. 
  The delay in the return to fertility following discontinuation of OC is due to both 
biological and behavioral factors.  Post-pill anovulation or dysfunctional ovulation 
following discontinuation of OC may explain the delay in fertility198, 208; however, this is 
unlikely because approximately 98% of women ovulate within three months following 
discontinuation of OC110.  The concentration of EE can effect the median time to 
conception following discontinuation of OC.  For example OC with EE doses ≥50 µg 
increase the median time to conception following discontinuation of OC by one month 
compared to OC containing < 50 µg EE195.  However, this factor is likely not responsible 
for the delay in fertility since OC containing ≥50 µg EE accounted for <2% of retail 
prescriptions written for OC in 1998 in the United States110.  Another mechanism 
responsible for the delay in fertility following discontinuation of OC may be due to 
continued hypothalamic suppression for a short period of time following discontinuation 
of OC.   
 A women’s parity can affect the delay in fertility following discontinuation of OC 
because nulliparous women took slightly longer to conceive than multiparous 
women197,198,201,203,208,209; however, this difference was reversed in Asian women200,205.  Oral 
contraceptives are often prescribed for non-contraceptive reasons (i.e., cycle regularity).  
Therefore, a higher proportion of women with infertility issues may use OC compared to 
non-hormonal contraceptives resulting in a falsely inflated interval of infertility following 
discontinuation of OC.  Conception rates decline as age increases in both men and women, 
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thus an older couple would likely take longer to conceive than a younger couple with 
similar health characteristics198,208.   
 Behavioral factors can also affect conception rates.  For example, the timing and 
frequency of intercourse, recall errors in determining when contraception was discontinued 
and “rounding up” while reporting the time at which conception occurred.  Accidental 
pregnancies that occur during non-hormonal contraceptive use are more likely to be 
reported as planned which would artificially decrease the time to conception in non-
hormonal contraceptive users.  Women who discontinue OC may take longer to conceive 
because they are more likely to refrain from attempting to conceive during the few months 
following contraceptive use to decrease the risk of residual effects of OC on the 
developing fetus.  It appears that the delay in fertility is likely due to a combination of both 
biological and behavioral factors.  Further research is needed to determine the exact 
mechanisms of action responsible for the delay in fertility following discontinuation of OC. 
 A number of researchers have reported conception rates follow an oscillatory 
pattern following discontinuation of OC with increases in conception rates occurring at 
approximately three to four month intervals199,200,202,209.  Janerich et al. suggest three different 
explanations for the oscillations in conception rates: (i) OC acts as a synchronizing agent 
resulting in previously unrecognized natural oscillatory cycles approximately four menstrual 
cycles in length, (ii) oscillations are caused by the transition of the reproductive organs 
from a suppressed state of functioning to an unsuppressed state, (iii) intrauterine mortality 
following OC use results in an infertile period202.  It is possible that the oscillations may be 
due to recall errors whereby women preferentially rounded their preconception intervals at 
one-quarter and one-half year199-201, 203.  Closer scrutiny of Pardthaisong and Gray’s data 
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suggests that they did not observe true “peaks” in conception rates but simply increases in 
conception rates three and six months following discontinuation of OC200.  Harlap and 
Baras reported conception rates do not follow an oscillatory pattern203.  These 
contradictory findings suggest that further research is needed to determine if conception 
rates exhibit an oscillatory pattern following discontinuation of OC use. 
1.3.13 Summary 
 Oral contraceptives have radically changed the way women approach 
contraception.  Initially OC were introduced to regulate menstrual disturbances and 
provide women with relief from menstrual related adverse events.  It appears that attempts 
to decrease the exposure to exogenous hormones results in inferior follicular suppression, 
particularly during the HFI or following missed doses.  It is unknown at this time as to why 
some follicles ovulate during compliant OC use while others regress.  Much research has 
examined various aspects of OC composition and function; however, we are far from 
completely understanding the exact mechanisms responsible for ovarian and uterine 
suppression during OC use.   
 Most women desire changes to their menstrual patterns whether it is a decrease in 
menstrual related side effects or changes to bleeding frequency.  Continuous OC use is 
associated with high acceptability and effectiveness while providing women with the 
desired changes in menstrual patterns.  Ovarian follicular development and the associated 
endocrine profiles have not yet been critically examined during continuous OC use.  
Further research needs to examine endometrial development and ovarian follicular growth, 
regression and ovulation during both conventional and continuous OC dosing schemes to 
develop a more effective, better accepted OC.  Furthermore, the information could be 
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used to develop new contraceptive technologies which could provide more contraceptive 
choices for women. 
 It has been well established that discontinuation of OC results in a two to three 
month lag in fertility compared to non-hormonal contraceptives.  Many hypotheses to 
explain the delay in fertility following discontinuation of OC have been elucidated; 
however, an acceptable mechanism of action to explain the decrease in fertility has not yet 
been suggested.  A better understanding of the exact effect OC administration has on the 
reproductive organs would likely aid in the explanation of the delay in fertility following 
discontinuation of OC. 
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Chapter 2 
GENERAL OBJECTIVES AND HYPOTHESES 
 
The general objectives of the studies contained in this thesis were: 
1. to assess ultrasonographic image attributes of dominant ovarian follicles during the 
final stages of development prior to ovulation in natural cycles and prior to peak 
estradiol concentrations for dominant anovulatory follicles during OC cycles; 
2. to characterize the development and ovulation of ovarian follicles and related 
endocrine changes, during and following discontinuation of the suppressive effects 
of continuous and conventional OC dosing schemes; and 
3. to elucidate the mechanisms of action responsible for the delay in fertility following 
discontinuation of OC. 
The research hypotheses tested were: 
1. Image attributes of follicles from natural cycles differ quantitatively from follicles 
that developed under the suppressive effects of OC. 
2. Continuous OC dosing schemes better suppress follicular development than 
conventional OC dosing schemes. 
3. A longer time interval to ovulation occurs following discontinuation of OC 
compared to the first day of menses to ovulation in natural cycles. 
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3.1 Abstract  
Objective:  Computer-assisted analyses were used to examine ultrasound image attributes 
of human dominant ovarian follicles that developed during natural and oral contraceptive 
cycles.  We hypothesized that image attributes of natural cycle follicles would differ 
quantitatively from those in oral contraceptive cycles and that oral contraceptive cycle 
follicles would possess image attributes indicative of atresia. 
Methods:  Dominant ovarian follicles of 18 clinically normal women were compared using 
image analysis techniques for the seven days before ovulation during a natural cycle (n=9) 
or the seven days before peak estradiol in women using oral contraception (n=11) in a 
retrospective study.  Follicles were analyzed using region and line techniques designed to 
compare the image attributes of numerical pixel value, pixel heterogeneity and area under 
the curve. 
Results: Numerical pixel value was higher in oral contraceptive cycle follicles with region 
analysis and tended to be higher with line analysis (p=0.005 and p=0.06, respectively).  No 
differences were observed in area under the curve and pixel heterogeneity measured with 
either technique, between natural and oral contraceptive cycle follicles. 
Conclusions:  The increased numerical pixel value of oral contraceptive cycle follicles and 
lack of differences in pixel heterogeneity and area under the curve values between natural 
cycle and oral contraceptive cycle follicles did not support the hypothesis that oral 
contraceptive cycle follicles would show ultrasonographically detectable signs of atresia.  
Image attributes observed in oral contraceptive cycle follicles were not clearly indicative of 
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atresia nor were they large enough to preclude preovulatory physiologic status in oral 
contraceptive cycle follicles. 
3.2 Introduction 
 Diagnostic gray-scale ultrasonography has revolutionized the study of ovarian 
biology in animals and humans because it allows researchers and clinicians to assess the 
development of individual follicles in a direct, non-invasive, and atraumatic manner 
without interruption or distortion of ovarian function1.  Prior to the introduction of 
ultrasonography, histological slices of ovarian tissue were used to elucidate ovarian 
follicular development; however, histologic investigation only provides information about a 
single time point and does not permit assessment of follicular function over time.  Further, 
histology cannot be used for time-series studies in humans. 
 Animal models have been developed to elucidate the basic mechanisms of ovarian 
function in humans and to overcome ethical objections of some aspects of research in 
humans.  To date, however, no appropriate animal models are available to elucidate the 
physiological effects of oral contraceptives (OC) on human ovarian function due to species 
specific differences in the metabolism of the exogenous estrogen and progestins used to 
control reproductive function. Non-invasive techniques do not yet exist that will allow for 
the determination of the physiological status of individual ovarian follicles with a single 
observation.  However, new technologies involving computer assisted image analysis to 
elucidate a follicle’s physiologic status show promise1,2.  
 Quantitative changes in ultrasound image echotexture as indicators of physiological 
function of ovarian structures have been described in domestic animal models3-8. The 
validity of the image analysis technique has been verified through correlation of ultrasound 
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image attributes with histologic attributes3,4,8.  Similar studies in humans are objectionable 
ethically; however, information generated in animal studies may be applied to human 
imaging based studies3-6,9,10.  The overall goal of this line of research in our laboratory is to 
elucidate physiologic status of dominant follicles with non-invasive ultrasonography in 
humans.  Imaging-based techniques that could be used to determine follicular health would 
obviate the ethical and logistical limitations associated with ovarian function research in 
women.  
 It has recently been reported that women grow follicles in two or three follicular 
waves during each natural menstrual cycle11,12.  The pattern of folliculogenesis is similar in 
women to those observed in several species of domestic animals (bovine, equine, caprine 
and ovine)10,13-17.  Follicular waves, in humans, are characterized by an increase in the 
number of follicles ≥ 5 mm in diameter, occurring in association with the growth of at least 
two follicles to ≥ 6 mm in diameter11.  Growth of all follicles in the cohort continues until 
one follicle is physiologically selected as the dominant follicle.  The dominant follicle 
continues its development to pre-ovulatory diameter while the remaining follicles in the 
cohort undergo atresia.  The dominant follicle will ovulate if the appropriate hormone 
signals (i.e., mid-cycle luteinizing hormone surge) are provided.  If the hormone signals 
which trigger ovulation are not provided, the dominant follicle enters a static phase and 
remains approximately the same diameter until it enters the regressing phase, when it 
decreases in diameter until it is no longer detectable.  
 Dominant follicles develop in women during adherent use of OC, with most 
dominant follicles initiating growth during the hormone free interval18-22.  Ovulatory 
follicles that develop during natural menstrual cycles are presumed to be healthy because 
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they usually ovulate.  It is not known whether dominant follicles that arise during OC use 
have the same physiologic status or ovulatory capacity as natural preovulatory follicles.   
 The primary objective of the present study was to assess ultrasonographic image 
attributes of dominant ovarian follicles during the final stages of development in natural 
menstrual cycles and OC cycles.  We hypothesized that image attributes of follicles from 
natural cycles will quantitatively differ from OC cycle follicles and that the image attributes 
of OC cycle follicles would be consistent with those indicative of atresia. 
3.3 Materials and Methods 
  This study was a retrospective, observational study designed to evaluate and 
compare ultrasound image attributes of dominant ovarian follicles (> 10 mm in diameter) 
during natural and OC cycles.  Images of twenty (n=20) dominant follicles were analyzed.  
The images were obtained in two previous studies designed to characterize ovarian 
follicular wave dynamics during natural cycles12,13 and OC cycles22.  Both study protocols 
were initially approved by the University of Saskatchewan Ethical Review Board.  The 
inclusion and exclusion criteria of both studies were similar.  Participants were assessed, by 
history and physical examination, to be healthy women of reproductive age (28.0 ± 0.14 
years, natural cycles; 24.5 ± 0.02 years, OC cycles; mean ± SEM).  All women in both 
studies had a history of normal menstrual cycles and did not use OC for a minimum of 
three months before participating.  In the OC trial, one of three different OC formulations 
were administered to thirty six women for three consecutive 28-day cycles; (i) 20 µg ethinyl 
estradiol (21)/100 µg levonogestrel (21) (n=7), (ii) 30 µg ethinyl estradiol (21)/150 µg 
desogestrel (21) (n=2), or (iii) 35 µg ethinyl estradiol (21)/180 µg norgestimate (7)/215 µg 
norgestimate (7)/250 µg norgestimate (7) (n=2).   Nine women grew 11 dominant follicles 
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during compliant OC use.  Two women grew dominant follicles during two separate cycles 
of OC-use; therefore, images from eleven dominant, ostensibly, ovulatory follicles were 
analyzed in the present study22. Images of nine dominant follicles from nine volunteers 
were randomly selected from natural cycle data to act as controls11,12.  Blood samples were 
drawn every third day for women in the natural cycle trial and every second day once a 
follicle reached > 14mm diameter for women in the OC cycle trial. 
 A high resolution ultrasound instrument equipped with 5-9 MHz multi-frequency 
intravaginal convex array transducer (ATL Ultramark HDI 5000, Advanced Technologies 
Laboratories, Bothwell, WA, USA) was used.  Settings of the ultrasound instrument that 
affect image attributes (beam focus, overall time-gain, near-field and far-field gain) were 
standardized to the same predetermined standards for both studies.  Each image was 
digitally acquired and transferred into a customized computer database during the 
ultrasound examinations.  Images of the dominant follicle acquired in largest cross-
sectional diameter with the fewest image artifacts were selected for image analysis.   All 
image analyses were performed by the same individual (RLB).  Blinding was not possible 
because each image contained identifying study information. 
 Image attributes of dominant follicles were analyzed using a graphics workstation 
equipped with a customized software (SYNERGYNE 2©, Saskatoon, SK, Canada) 
integrating complex algorithms designed for ultrasonographic image analysis1,2.  Each 
image was analyzed with two different techniques: (i) region analysis, and (ii) line analysis 
designed to quantify gray-scale values of selected regions1,2.  Three image attributes were 
quantified: (i) numerical pixel value (NPV) defined as the mean pixel gray-scale value of the 
sampled pixels, (ii) pixel heterogeneity (PH) defined as the standard deviation of the mean 
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gray-scale values of the sampled pixels, and (iii) area under the curve (AUC) defined as the 
total sum of the gray-scale values within the sampled region. 
 Briefly, region analyses involve overlaying a computer-generated grid onto a 
selected area of the 2-dimensional image of a follicle to generate a 3-dimensional 
framework representing processed pixel intensities.  Placing a computer-generated opaque 
“film” or blanket over the wire framework representing pixel values comprising the 
ultrasound image yields a 3-dimensional contoured surface.  This technique allows 
discriminatory examination of the surfaces and rapid visual assessment of ultrasonographic 
attributes associated with follicle health (state of viability or atresia)2.  Region analyses were 
used to measure NPV, PH and AUC within a region of the follicle wall.  A one-pixel-wide 
line was used to outline and isolate the largest continuous portion of follicular wall 
extending from the peripheral antrum to the stroma with the fewest image artifacts.  The 
antrum-wall interface was defined as the last pixel along the line in which a sequential rise 
in gray-scale occurred45.   
 Line analysis places a line across a specified section of the image of the follicle to 
produce a graph of the pixel intensities along the line displayed.  The graph depicts the 
amplitude of the echoes located along the line3.  Line analysis was used to measure NPV, 
PH and AUC of a single line across the follicle wall from the antrum-wall interface to the 
ovarian stroma using two straight three-pixel wide lines.  The two linear measurements 
were taken between the 4 and 9 o’clock positions of the follicle image. 
 Ovulation was defined as the disappearance of a follicle greater than 15 mm in 
diameter identified the previous day and confirmed with visualization of a corpus 
luteum12,13,24,25.  Ovulation was used as a reference point (Day 0) to standardize the data for 
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natural cycle follicles.  No follicles ovulated during OC cycles; therefore, OC cycle follicles 
were standardized to the day of peak estradiol concentration (Day 0) which was also 
defined as the last day of the growth phase.  The day of peak estradiol concentration for 
each individual was determined by reviewing the estradiol profiles for each woman in the 
OC trial22.    
 Ultrasound images were available for each of the seven days leading to ovulation 
for women in the natural cycle study and approximately every second day for seven days 
leading to peak estradiol levels for women participating in the OC trial.   Data were 
standardized by aligning data from Day 0 as defined for each group.   Image attributes on 
each of the seven days (Days -1 to -7) leading to ovulation during the natural cycle were 
compared to the corresponding days (Day -1 to -7) leading to peak estradiol concentrations 
during the OC cycle.  Data were inadequate for statistical comparison of image attributes 
among the three different OC formulations, therefore data were combined.   
 Image attributes were compared using repeated measures analysis of variance 
(PROC MIXED, SAS/STAT, v8) for main effects of time and follicle type.  Significance 
was set at p<0.05.  Results are expressed as the mean ± SEM. 
3.4 Results 
          Peak estradiol-17β concentrations for OC cycle follicles were 170.1 ± 30.4 pg/ml 
(range, 35.1 – 364.5 pg/ml)22.  Mean follicle diameter of OC cycle follicles at peak estradiol 
concentrations was 20.3 ± 2.0 mm.  Mean estradiol concentrations for natural cycle 
follicles on Day –1 were 190.8 ± 19.6 pg/ml (range 20.0 - 340 pg/ml)11.  Mean follicle 
diameter of natural cycle follicles on Day –1 was 21.1 ± 1.1 mm.  Mean growth profiles for 
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natural and OC cycle follicles are displayed in Figure 3.1.  Ultrasonographic images of a 
natural cycle follicle one day before ovulation and an OC cycle follicle on the day of peak 
estradiol are shown (Figure 3.2, a and b, respectively). 
 Numerical pixel values were higher (p=0.005) for OC cycle follicles versus natural 
cycle follicles using region analyses and tended to be higher (p=0.06) using line analysis for 
the seven days prior to Day 0.   Oral contraceptive cycle follicles had visually similar NPV 
for both region and line analyses; however, the values were initially high and then 
decreased to a nadir at Day -3 (region analysis) or Day -4 (line analysis) after which they 
increased until Day -1 and subsequently decreased on Day 0 (Figure 3.3 a, b).  Numerical 
pixel values for natural cycle follicles progressively increased from Day -7 (Region analysis; 
31.64 ± 4.26, Line analysis; 41.66 ± 10.49) to Day 0 using line analysis (64.03 ± 6.37; 
p=0.01) and tended to increase (43.80 ± 5.30; p=0.08) with region analysis                
(Figure 3.3 a, b).   
 Pixel heterogeneity values were not different between natural and OC cycle follicles 
for either region or line analyses (p=0.113 and p=0.515, respectively).  No changes were 
observed over the seven days prior to Day 0. 
 Area under the curve evaluated using line analyses tended to be higher (p<0.09) in 
OC cycle follicles; however, no differences were observed (p=0.23) in follicle type using 
region analyses.  Values for AUC for both natural and OC cycles increased as the interval 
to Day 0 decreased. 
Nadirs in image attributes for the values representing AUC and PH were observed 
on Day -4 (Figure 3.3 c-f).   
 57
0-8 -6 -4 -2
5
10
15
20
25 OC cycle
Natural cycle
Day
Fo
lli
cl
e 
D
ia
m
te
r 
(m
m
)
Figure 3.1: Growth profiles of natural and OC cycle follicles 
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Figure 3.2: Ultrasonographic images of a natural cycle and OC cycle follicles.  
        (a) Natural cycle follicle on Day 0, (b) OC cycle follicle on Day 0. 
 
 
 
 
 
 
 
 
 
 
a) b) 
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Figure 3.3: Graphical representation of NPV, PH and AUC.  Mean ± SEM (a, b) 
numerical pixel value (c,d) pixel heterogeneity and (e, f) area  under the curve 
obtained by region analysis (a, c, e) and line analysis (b, d, f) of natural cycle 
and OC-cycle follicles. 
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3.5 Discussion 
 The study of ovarian follicular dynamics in women taking hormonal contraceptives 
is a relatively new research area with profound clinical relevance.  Follicular development in 
up to 50% of new OC cycles and up to a 25% ovulation rate have been reported18.  Most 
follicular development observed in OC cycles is initiated during the hormone free interval 
of the OC cycle22.  The objective of this study was to assess the indicators of follicular 
physiological status in women by comparing ultrasound image attributes of human 
dominant ovarian follicles leading to ovulation in natural cycles or peak estradiol 
concentrations in OC cycles.  Numerical pixel values representing the relative brightness of 
the elements comprising the ultrasound image were the only image attributes that differed 
between natural and OC cycle follicles.  Morphologic changes indicative of atresia in 
animal models are typically represented by high values of NPV4,6.  These morphologic 
changes include but are not limited to: (i) an increase in the number of multivesicular 
bodies, (ii) lipid droplets and vacuoles within granulosa cells, (iii) dilation of the smooth 
endoplasmic reticulum and golgi apparatus and (iv) thecal cell hypertrophy/degeneration; 
which, when taken together, appear to affect the tissue properties enough to change the 
image attributes25,26.  Although NPV were greater in OC cycle follicles, the increased values 
were not high enough to indicate poor physiologic status as described in studies using 
animal models4,6.  The hypotheses that image attributes of natural and OC cycle would 
quantitatively differ and that OC cycle follicles would possess image attributes 
characteristic of atresia were only partially supported. 
 An interesting common observation in all image attributes of OC follicles that were 
evaluated fell to a nadir at Day -4, suggesting that an important physiological event occurs 
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approximately four days before peak estradiol concentrations were attained.  The image 
attributes of the values reflected in NPV and AUC in both natural and OC cycle follicles 
tended to increase from Day -4 to Day 0.  This observation may be interpreted to mean 
that the follicles in both natural and OC cycles have similar physiologic status and undergo 
similar changes during the final stages of development.  Classically described, ovulatory 
changes include thickening of the follicle wall, development of lipid inclusion granulosa 
and theca cells, hypertrophy of theca cells and increased vascularization of the theca 
layer27,28.  Taken together, these developmental changes may be reflected as increases in 
AUC as the follicle wall thickens and increases in NPV as the follicle wall develops to fulfill 
its biological functions.  Further research is needed to determine the physiologic changes 
responsible for changes in image attributes. 
No OC cycle follicles analyzed in the present study ovulated.  However, we suggest 
that follicles which develop during compliant OC use may differ in ovulatory potential 
because ovulation has been documented in up to 25% of follicles which develop to 
ostensibly ovulatory diameter during compliant OC use18.  Differences in OC formulations 
(i.e. estradiol concentrations and progestin type and associated activity) may have different 
physiological effects on follicular development and subsequent ovulatory ability, and 
individual responses to the different estrogen levels and the various progestins used in OC 
formulations may affect ovulatory ability differently.  The authors were unable to test this 
hypothesis directly in the present study.  Variations in image attributes of OC cycle follicles 
may be due to differences in physiologic status and ovulatory ability.  Further research to 
determine the physiological mechanisms responsible for differences in ovulatory ability of 
OC cycle follicles needs to be undertaken.” 
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Studies in domestic animals have demonstrated that ultrasound image attributes of 
ovarian structures are related to their physiologic function3,4,8.  The present study provides 
rationale for exploring the hypothesis that the same is true for humans.  In order to have a 
complete understanding of the relationship between image attributes and follicular 
development in humans, we must assess all stages of follicular development throughout the 
menstrual cycle, prediction of dysfunctional follicular development (i.e., hemorrhagic 
anovulatory follicles) and the effects of different OC formulations on follicle development.  
Once the association between image attributes and various conditions of follicular 
development are determined, follicular status could be assessed with a single ultrasound 
examination, obviating many ethical constraints that currently prevent progress in human 
ovarian follicular research. 
 Ovarian follicles provide a unique endocrine environment fundamental to normal 
oocyte development and competence. Abnormal follicular development can lead to 
incompetent oocytes; therefore it follows that image attributes of the follicle wall may be 
related to oocyte competence.  Currently, image attributes only provide us with 
information about the physiologic status of the follicular wall.  Image analyses do not 
provide information about the health and viability of the oocyte; however, this area is 
under active investigation7. 
 The primary objective of this research was to evaluate and compare ultrasound 
image attributes of dominant follicles that develop during natural cycles and OC cycles.  
We were not able to examine the effect of different OC formulations on image attributes 
due to constraints imposed by the study design.  It is hoped that future research will 
explore the effects of different OC formulations on the image attributes of dominant 
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follicles.  Research to evaluate physiologic status may well hinge upon follicular response to 
administration of ovulation inducing doses of recombinant human chorionic gonadotropin 
in women who develop dominant follicles during OC cycles in concert with development 
of an animal model to test the biological effects of varying doses of ethinyl estradiol or 
different progestins on follicle and oocyte status. 
 In conclusion, similarities in image attributes between natural and OC cycle follicles 
provides preliminary evidence that ultrasound image attributes of human follicles are 
associated with physiologic status during the growth phase and that follicles which develop 
during OC cycles have image attributes similar to those of natural cycle follicles.  Only one 
of the three image attributes studied differed between natural and OC cycle follicles.  The 
changes observed in OC cycle follicles were not clearly indicative of atresia nor were they 
large enough to preclude preovulatory physiologic status in OC cycle follicles. 
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4.1 Abstract 
Objective: Characterize ovarian follicular and endometrial development during 
conventional versus continuous oral contraceptive (OC) dosing regimens to explore 
follicular development during the hormone free interval and examine follicular 
development following OC discontinuation.   
Methods: Transvaginal ultrasonography and blood sampling were done to ascertain 
ovarian function.   
Results: Fewer follicles >4 mm developed during continuous versus conventional OC use 
(p=0.006).  No dominant follicles developed during continuous OC use versus eight 
dominant follicles (16.1 ± 3.3 mm) during the conventional OC regimen.  Two of eight 
(25%) dominant follicles ovulated.  All dominant follicles began development during the 
HFI.  Following discontinuation of OC ovulation took approximately five days longer 
when compared to natural cycles. 
Conclusion: Continuous OC regimens more effectively prevent dominant follicle 
development and breakthrough ovulation.   The slight delay in time to ovulation following 
OC discontinuation and natural cycles could be attributed to suppression of follicle wave 
activity. 
4.2 Introduction 
Since their introduction in the late 1950's, oral contraceptives (OC) have been 
traditionally prescribed in schemes consisting of 28 day cycles comprised of 21 daily active 
pills followed by a seven day hormone free interval.  The conventional dosing scheme was 
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developed to mimic the physiologic event of monthly menstruation in nonpregnant women 
and to provide the illusion of natural menstrual cyclicity.  The hormone free interval is 
reported to have no physiologic benefit, but was initially included to increase user 
acceptability1.   Oral contraceptive withdrawal symptoms associated with the hormone free 
interval include: bleeding, pain, breast tenderness, bloating, swelling, migraines, 
premenstrual syndrome, acne, back pain, dysmenorrhea, anemia, increased use of 
analgesics and a higher incidence of follicular cyst development2,3. 
Twenty-eight years ago, Loudon et al. reported that three months of continuous 
OC use suppressed monthly menstruation, was accepted by women and prevented 
pregnancy in all study volunteers4; yet no changes in OC regimens were introduced5.  Since 
then, the efficacy and acceptability of continuous dosing schemes have been examined6-17; 
however, the physiologic effect of continuous OC use on follicular and endometrial 
development has been examined in only two studies5,18.   
Ultrasonography allows assessment of ovarian follicular development at key points, 
such as during the hormone free interval, and may be combined with hormone assays and 
image analysis techniques to determine the physiologic status of a follicle19-21.  The loss of 
endocrine suppression during the hormone free interval is suggested to provide an 
environment conducive to follicular development due to increases in endogenous follicle 
stimulating hormone (FSH)2,22.  Dominant follicles have been observed during adherent 
OC use2,23-27 and a proportion of these follicles continue development to pre-ovulatory 
diameter2,23,25,27-29.  It has been shown that over 85% of dominant follicle development is 
initiated during the hormone free interval2 and ovulation of up to 50% of pre-ovulatory 
sized follicles, depending on the OC formulation, has been reported27.  
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  Ultrasonography has been used to assess the ovarian activity during continuous OC 
use in only one known study.  Schlaff et al. compared follicular development during two 
consecutive 28-day cycles of either: (i) 20 µg ethinyl estradiol (EE)/100 µg levonorgestrel 
for 21 days followed by a seven day hormone free interval, (ii) 20 µg EE/150 µg 
desogestrel followed by two days of placebo then 10 µg EE for five days, or (iii) 28 days of 
20 µg EE /150 µg desogestrel18.  Weekly ultrasound examinations in combination with 
endocrine profiles were used to monitor follicular development ≥8 mm in diameter.  
Dosing schemes with a seven day hormone free interval provided the least follicular 
suppression18. The proportion of follicles which manifested dominance and the number of 
“escape” ovulations during the three dosing schemes, were not reported.  An intensive 
ultrasound examination schedule in combination with endocrine profiles has not yet been 
used to examine ovarian follicular and endometrial development during continuous OC 
dosing schemes. 
Since their introduction, OC have become the most popular reversible 
contraception chosen by women residing in industrialized nations30.  Therefore, it is 
essential to determine if OC have residual effects on reproductive function following their 
discontinuation when fertility is desired.  Fertility is temporarily reduced for approximately 
two to three months following discontinuation of conventional OC compared to 
discontinuation of non-hormonal contraceptives (i.e., intrauterine device, diaphragm, or 
condom)31-40.  Approximately half of all women (39% - 56%) conceive within three months 
of discontinuing conventionally administered OC36,41,42 which is slightly lower than for 
women using other methods of contraception (e.g., intrauterine device, diaphragm and 
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“other” contraceptive methods; 54% - 65%)41.  Follicular kinetics following discontinuation 
of continuous OC dosing schemes apparently have not yet been examined. 
The objectives of the present study were to characterize ovarian follicular and 
endometrial development during and following discontinuation of conventional versus 
continuous regimens of two different OC formulations using high-resolution transvaginal 
ultrasonography.  We hypothesized that the continuous OC dosing scheme would better 
suppress ovarian follicular development during the first three cycles of use and that the 
interval from discontinuation of OC to ovulation would be longer than that from 
menstruation to ovulation in natural cycles. 
4.3 Materials and Methods 
The present study was a randomized, single center trial.  Informed consent was 
obtained from all volunteers before performing any study procedures.  The study protocol 
was approved by the University of Saskatchewan Biomedical Ethics Review Board.  Thirty-
six women between the ages of 18 and 35 (24.4 ± 0.7 years and BMI 24.3 ± 0.9; mean ± 
SEM) were enrolled.  Volunteers were assessed to be healthy women by history and 
physical examination.  Information on body mass index, gravidity, parity, and previous OC 
use were collected from each woman.  Women were excluded if they smoked, were 
pregnant or lactated within 6 months of enrolling in the study, had used OC in the 
previous two months, had a history of irregular menstrual cycles, were using 
contraindicated medications, or were planning surgery during the study period.   
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Each woman received one of two different monophasic OC formulations in a 
continuous or conventional dosing scheme for three 28-day cycles.  The four study groups 
were:  
(i)  30 µg EE /150 µg levonogestrel (LNG) (21 days and 7 day HFI; n=8);  
(ii) 30 µg EE/150 µg LNG (28 days; n=9);  
(iii) 35 µg EE/250 µg norgestimate (NGM; 21 days and 7 day HFI; n=8);  
(iv) 35 µg EE /250 µg NGM (28 days; n=11).    
Oral contraceptives were initiated on the first day of menses during Cycle 1.  The 
conventional regimen consisted of 21 days of daily active pills followed by a seven day 
hormone free interval.  The continuous regimen consisted of 28 daily active pills with no 
hormone free interval.  Women did not take OC during the fourth and final cycle of the 
study.  
Ovarian follicular and endometrial development were monitored throughout the 
study with high-resolution transvaginal ultrasonography (ATL HDI 5000, Advanced 
Technologies Laboratories, Bothwell, WA, USA) as described19.  Approximately 90% of 
the examinations were performed by one individual (RLB).  A second investigator (RAP) 
performed examinations when the primary ultrasonographer was unavailable.  Diameters 
of all follicles ≥ 2mm, endometrial thickness and echotextural pattern (i.e., M, A, B, C or 
D) were recorded during each ultrasound examination19,20,43.   
The scanning schedule was designed to capture key physiological processes of 
follicular and endometrial development and was based on previous studies which 
characterized follicular wave dynamics during natural and OC cycles2,19,20.   Monitoring 
began on Cycle 1 day 7 and continued every seven days for the first 21 days of Cycle 1.  
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After Cycle 1 Day 21, an every third day ultrasound scanning schedule was followed until 
Cycle 3 Day 28.  If a follicle grew ≥14 mm in diameter during Cycles 1 to 3, daily blood 
sampling and ultrasound examinations were performed until the physiologic status of the 
follicle was determined [i.e., ovulation, regression or haemorrhagic anovulatory follicle 
(HAF)].  Ovulation was defined as the disappearance of a follicle ≥15 mm in diameter 
detected ultrasonographically the previous day followed by the subsequent visualization of 
a corpus luteum44,45.  
Ultrasound examinations for Cycle 4 began on Cycle 4 Day 2 and continued every 
second day.  Daily ultrasound examinations commenced when a follicle reached ≥16 mm 
in diameter and continued until the physiologic fate of the follicle was determined.  Blood 
samples were taken during Cycle 4 when a follicle first reached 18 ± 1 mm and 20 ± 1 mm, 
and were assayed for estradiol-17β. A final ultrasound examination and blood sample were 
completed six to nine days post-ovulation to image the corpus luteum and correlate corpus 
luteum morphology to serum progesterone levels43. 
Data from 18 women who participated in a previous study designed to characterize 
ovarian follicular wave dynamics during natural cycles were selected randomly and used as 
historical controls for comparison of Cycle 4 endpoints19,20.  Inclusion and exclusion 
criteria and ultrasound imaging techniques for the natural cycle study were similar to the 
present study.  Cycle 4 Day 1 was defined as the first day of menses during natural cycles 
or the first day following cessation of OC for follicles developing after discontinuation of 
OC.  The first day following discontinuation of OC was chosen as the comparator for 
Cycle 4 Day 1 because the high incidence of unscheduled bleeding at the time of OC 
 73
discontinuation made it difficult to accurately determine Day 1 of menses in women 
discontinuing OC. 
Volunteers were assigned a diary card for all four cycles to record OC initiation, 
missed pills, concomitant medication used during each cycle, menstrual patterns and 
adverse events.  Diary cards were reviewed with each volunteer at the conclusion of each 
cycle.  Oral contraceptive use was reviewed during each visit to minimize missed doses. 
The growth profiles of all follicles which grew ≥4 mm were retrospectively 
determined as described and graphed for each dosing scheme2,19,20,44,45.  The day of selection 
was defined as the day prior to the manifest of dominance.  The day dominance was 
manifest was defined as the day the largest follicle of the cohort surpassed all other follicles 
by ≥2 mm in diameter.  Pre-ovulatory diameter was defined as diameter the day before 
ovulation was observed.   
Repeated measures analyses of variance were used to compare follicle diameter, 
endometrial thickness and pattern between regimens during Cycles 1 to 3 (PROX MIXED, 
SAS/STAT software, 2004). Mann-Whitney U tests were used to examine differences in 
bleeding patterns during Cycles 1 to 3 and to compare Cycle 4 endpoints between 
continuous and conventional regimens (SPSS Version 12, 2004).  Kruskal-Wallis tests were 
used to compare estradiol-17β concentrations of follicles 18 ± 1 mm and endpoints during 
Cycle 4, among OC study groups and the reference cycles (SPSS Version 12, 2004).  
Significance was set at p<0.05.  Results are expressed as the mean ± SEM. 
 
 
 74
4.4 Results 
Data for all endpoints were analyzed initially for differences between OC 
formulations within a dosing scheme as well as differences between the continuous and 
conventional dosing schemes.  No statistical differences were observed within dosing 
schemes; therefore, data were combined. 
Cycles 1-3 
Overall, fewer follicles developed during continuous OC use than conventional OC 
use (p<0.001).  Follicle number, regardless of size, decreased as time progressed from 
Cycles 1 to 3 for both continuous and conventional regimens (p<0.001).  More follicles >4 
mm in diameter were observed during conventional OC use compared to continuous OC 
use (p=0.006). The number of follicles >4 mm during conventional OC use increased 
during the hormone free interval of Cycles 1 through 3 (p<0.001; Figure 4.1).   
Representative follicular growth profiles from continuous and conventional regimens are 
shown (Figure 4.2).  Little to no follicular development was observed during continuous 
dosing schemes whereas follicular development was initiated during the hormone free 
interval of conventional dosing schemes. 
More dominant follicles (≥10 mm) developed during conventional OC than 
continuous OC use (8 versus 0, respectively; p=0.01).  All dominant follicles began 
growing during the hormone free interval.  Five dominant follicles developed during the 
use of 30 µg EE (21)/150 µg LNG (21) and three dominant follicles development during 
the use of 35 µg EE (21)/250 µg NGM (21).  One dominant follicle from each 
conventionally administered OC ovulated (25%; Figure 4.3).  The follicle which ovulated in 
the 30 µg EE (21)/150 µg LNG (21) group had no detectable estradiol output for the No 
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Figure 4.1: Follicle numbers for follicles ≤4 mm, and > 4 mm in diameter during 
          continuous and conventional OC use Cycles 1 to 3. 
 
 
 
 
 
 
 
 
 
 
Follicle >4mm 
Treatment: p=0.006 
Day: p<0.0001 
Treatment*Day: p<0.0001 
Follicles ≤4mm 
Treatment: p=0.67 
Day: p<0.0001 
Treatment*Day: p=0.55 
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Figure 4.2: Representative follicular growth profiles during (a) continuous and  
  (b) conventional OC use. 
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Figure 4.3: Growth profiles and serum estradiol concentrations of follicles that ovulated 
        during adherent conventional OC use. 
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seven days prior to its ovulation.  A corpus luteum was visualized ultrasonographically and 
the serum progesterone level observed on Day 6 post-ovulation was 0.79 ng/ml.  The 
follicle which ovulated in the 35 µg EE (21)/250 µg NGM (21) group exhibited clinically 
normal serum estradiol concentrations for the pre-ovulatory period.  The progesterone 
level observed on Day 8 post-ovulation was 3.5 ng/ml. 
Endometrial thickness for the continuous OC groups remained stable from Cycles 1 to 3 
(Figure 4.4).  Decreases in endometrial thickness attributed to menstrual bleeding were 
observed during the hormone free interval of the conventional OC groups (Figure 4.4).  
No differences were observed between continuous and conventional dosing schemes for 
endometrial thickness (p=0.57) or endometrial pattern (p=0.71).   
Women using continuous OC experienced more total days of flow and spotting 
(p<0.05) than women using conventional OC.  No differences were observed between 
continuous and conventional regimens during Cycle 1 in the number of days of spotting, 
light flow or heavy flow (p>0.46).  Women using continuous OC experienced more days of 
spotting in Cycle 2 and 3 (p<0.006), more days light flow in Cycle 2 (p=0.03) and tended to 
have more days of light flow in Cycle 3 (p=0.09).  Women using continuous OC had fewer 
days of heavy flow in Cycle 2 (p=0.01) and tended to have fewer days of heavy flow in 
Cycle 3 (p=0.08).  Differences were not observed in the number of days of spotting, light 
flow or heavy flow between the two OC formulations within a dosing scheme (p=0.10). 
 Cycle Four 
One woman was excluded from analysis of Cycle 4 endpoints because she did not 
experience menses, or an ovulatory event, by Cycle 4 Day 63 (12 standard deviations from  
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Figure 4.4: Endometrial thickness during Cycles 1 to 3 during continuous and 
                    conventional OC use. 
 
 
 
 
 
 
 
 
Treatment: p = 0.57 
Day: p<0.0001 
Treatment*Day: p<0.0001 
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the mean).  Therefore, 35 women were included in the analysis of Cycle 4 endpoints 
following discontinuation of conventional OC (n=15) and continuous OC (n=20). 
Cycle 4 endpoints are shown in Table 4.1.  Selection took approximately three days 
longer (p<0.001) and dominance was manifest approximately two days later (p < 0.001) 
following discontinuation of OC than for natural cycles.  Irrespective of their groups it 
took approximately five days longer for follicles to ovulate once OC were discontinued 
compared to natural cycle follicles (p<0.001).  
In the conventional dosing group, 14 of the 15 women (93%) grew pre-ovulatory 
sized follicles (Table 4.1).  Twelve of 14 follicles (86%) ovulated and the remaining two 
follicles (14%) formed a HAF.  The woman who did not develop a pre-ovulatory follicle 
during Cycle 4 had developed a dominant follicle during the hormone free interval which 
reached pre-ovulatory diameter mid-cycle, persisted and regressed.  In the continuous 
dosing group, all women developed a pre-ovulatory sized follicle (100%; Table 4.1).  
Thirteen of the 20 women (65%) developed a single pre-ovulatory follicle which ovulated 
and four women (20%) grew two pre-ovulatory sized follicles.  Three of the four women 
with two dominant follicles had one follicle that ovulated and one follicle that regressed; 
the fourth woman formed a HAF and the remaining follicle regressed.  One woman (5%) 
grew three pre-ovulatory sized follicles during Cycle 4; two of which ovulated and one 
regressed.  The remaining two women developed a HAF.   
Serum estradiol concentrations at a follicle diameter of 18 ± 1 mm were analyzed 
from 15 of the 17 women (88%) following continuous OC, 11 of the 12 women (92%) 
following conventional OC and 14 of the 18 women (78%) from natural cycles.  Two 
women in the continuous OC group and one woman in the conventional OC group were  
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Table 4.1:  Selection of the dominant and subordinate follicles (mean ± SEM), day to    
ovulation (mean ± SEM), estradiol concentrations, and follicle growth rates 
in natural cycles and in women following discontinuation of conventional and 
continuous OC regimens. 
 
 Continuous 
OC 
Conventional 
OC 
Natural 
Cycles 
Day of selection 13.1 ±  0.7a 13.0 ± 1.1a 8.6 ± 0.5b 
Day dominance was manifest 12.1 ± 0.3a 12.7 ± 0.6a 9.6 ± 0.5b 
Days to ovulation from Day 1 menses 
(natural) or discontinuation of OC 
20.3 ± 0.7a 20.5 ± 1.0a 15.1 ± 0.5b 
Days to ovulation from dominance 7.1 ± 0.5a 7.5 ± 0.5a 6.5 ± 0.3a 
Dominant follicle diameter (mm) 14.2 ± 0.7a 14.0 ± 1.1a 12.3 ± 0.4a 
Ovulatory diameter (mm) 21.4 ± 0.8a 21.2 ± 0.8a 21.8 ± 0.7a 
# females developing pre-ovulatory 
(>14 mm) sized follicles (%) 
20/20 (100)a 14/15 (93)a 15/15 (100)a
Follicle Growth Rate (mm/day) 1.1a 1.1a 1.4b 
Estradiol concentration* (pg/ml) 172.5 ± 22.0a 178.3 ± 23.2a 105.6 ± 2.7b
Progesterone concentrations 6-9 days 
post ovulation (ng/ml) 
12.3 ± 12.5a 16.8 ± 19.0a -- 
*Serum estradiol concentrations were measured when follicles were 18 ± 1 mm in OC 
cycles and 18 ± 2 mm in natural cycles  
a,b Within rows values with no common superscripts are different 
Significance indicated at p<0.05 
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unable to provide a blood samples when the dominant follicle was 18 ± 1 mm and a 
stratified blood sampling schedule during the natural cycle study prevented the 
determination of serum estradiol concentrations at the comparable follicular diameter for 
four preovulatory follicles.  Serum estradiol concentrations at 18 mm are shown in Table 
4.1.  No differences in estradiol concentrations were observed between OC formulations 
within a dosing scheme (p>0.26), or following discontinuation of continuous versus 
conventional dosing schemes (p=0.74); however, women discontinuing OC in the present 
study exhibited higher (p<0.03) estradiol concentrations than observed in the natural cycle 
reference cycles. 
  Blood samples taken six to nine days following ovulation were obtained from 15 of 
the 17 women (88%) in the continuous OC group and ten of the 12 women (83%) in the 
conventional OC group.  Two women from each OC dosing scheme were unable to 
provide a blood sample.  Serum progesterone levels are listed in Table 4.1.  In the 
continuous OC group, nine of 15 women (60%) had clinically normal progesterone levels 
(i.e., 6-24 ng/ml); five of the 15 women (33%) had progesterone levels <6 ng/ml and the 
remaining woman (7%) had progesterone levels >24 ng/ml.  In the conventional OC 
group, six of the ten women (60%) had clinically normal levels of progesterone; two (20%) 
had progesterone levels <6 ng/ml and two (20%) had progesterone levels >24 ng/ml.   
Progesterone levels did not differ between OC formulations within a dosing scheme 
(p>0.60) or between dosing schemes (p=0.22). 
4.5 Discussion 
Our hypothesis that a continuous OC regimen would suppress follicular 
development more effectively than conventional OC dosing was supported.  The number 
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of follicles ≤4 mm in diameter did not differ between dosing schemes; however, 
continuous OC dosing suppressed the development of follicles >4 mm and did not permit 
dominant follicle development.  The number of follicles, regardless of size, decreased 
slightly as the duration of OC use increased suggesting that the suppressive effects of OC 
on follicular populations increases with prolonged use.  We suggest that a decrease in the 
number of developing follicles may be attributed to recruitment of fewer follicles into the 
growing pool due to increased hypothalamo-pituitary-ovarian axis suppression with each 
subsequent cycle of OC administration.  Further research needs to examine the idea that 
increased duration of OC use is correlated to progressively increased suppression of 
follicular development, particularly during the hormone free interval. 
All dominant follicles that developed during conventional OC use initiated their 
growth during the hormone free interval, consistent with a previous report that 86% of 
dominant follicles initiated their development during the hormone free interval2.  A new 
follicular wave is initiated by a nadir in circulating FSH levels followed by two to three days 
of increase19.  Fauser et al. have demonstrated that the lowest FSH concentrations of the 
HFI are from Day 1 to 3 and are followed by five days of increasing FSH levels22.  Thus, 
we suggest that follicular development in OC cycles is manifest by this mechanism.  
Initiation of the next pill strip following the hormone free interval results in decreased FSH 
concentrations regardless of the presence of a dominant follicle46.  However, it is clear that 
the decreased dependence of the dominant follicle on gonadotropins allows some follicles 
to continue developing to preovulatory diameter and to ovulate if the proper hormonal 
cues are present, while subordinate follicles undergo atresia2,27,47-53.  Conventional dosing 
schemes appeared to provide cyclic increases in FSH during each hormone free interval 
resulting in follicular growth >4 mm, whereas continuous dosing schemes maintained 
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suppression of gonadotropins to basal levels resulting in suppression of most follicular 
growth >4 mm. 
It was interesting that the number of follicles ≤4 mm in diameter did not differ 
between continuous and conventional OC regimens.  Follicles ≤4 mm require basal levels 
of gonadotropins to sustain growth but are not yet fully responsive to cyclic changes in 
gonadotropins54.  The total number of follicles ≤4 mm in diameter did not increase during 
the hormone free interval of conventional OC use 22.   We suggest that OC do not affect 
the basal level of gonadotropins required to allow follicles into the recruitable pool, but do 
suppress endogenous cyclic increases in gonadotropins.  An environment with basal levels 
of gonadotropins would permit follicular development ≤4 mm in diameter but would 
suppress follicular development >4 mm, consistent with our observations. 
Our hypothesis that follicles would take longer to ovulate following discontinuation 
of OC than following initiation of menses during natural cycles was supported.  It took 
longer for selection, dominance to become manifest and ovulation, irrespective of the OC 
dosing scheme.  It has been well established that follicles which develop during natural 
cycles are recruited and begin to grow during the late luteal phase54.  The longer interval to 
selection, dominance and ovulation in follicles following cessation of OC may be due to 
follicular recruitment occurring before the first day of menses during natural cycles and 
after the comparable time point in follicles following discontinuation of OC.  It is also 
possible that OC synchronize follicular wave development such that follicles are at an 
earlier stage of development and take longer to attain selection, dominance and ovulation 
than natural cycle follicles.  The difference between the times of selection, dominance and 
ovulation was only a few days and could not explain the two to three month lag in fertility 
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following discontinuation of OC.  We interpreted these data to mean that other 
mechanisms are responsible for the delay in fertility. 
The serum estradiol levels were higher in women in the OC groups compared to 
women in natural cycles.  However, the estradiol concentration from follicles developing 
during natural cycles and following OC cessation were both well within the clinically 
normal range, suggesting that follicles from both groups were physiologically similar.  
Further research is needed to determine if the elevated level of estrogen following 
discontinuation of OC negatively effects follicular development and oocyte competence.  
In a previous study, follicles which developed during natural and OC cycles had similar 
ultrasound image attributes which was interpreted to mean that follicles which developed 
during different hormonal conditions had similar physiologic function21.  Further support 
for this hypothesis is by the observations of follicle development and ovulation in women 
during compliant use of several types of currently prescribed OC27.  Similarities in the size 
of dominant follicles at selection, dominance and ovulation, as well as similarities in the 
interval from the manifestation of dominance to ovulation between natural cycle follicles 
and follicles which develop following discontinuation of OC further supports the 
hypothesis of similar physiologic function between these follicle types.   
Clinically abnormal progesterone concentrations were observed following ovulation 
in approximately 40% of women following discontinuation of OC.  Thus, reduced fertility 
following discontinuation of OC may be hypothesized to be due to luteal dysfunction 
following ovulation.  This is only one possible explanation for the delay in fertility and 
further investigations are required before a cause and effect relationship could be 
established.     
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Factors other than anovulation in the cycle following OC cessation are likely 
responsible for the two to three month lag in the return to fertility.  It is possible that 
previous OC use has negative residual effects on oocyte growth and development resulting 
in reduced oocyte competence.  Novel image analysis techniques are currently under 
development to determine the physiologic status of a follicle and oocyte competence with a 
single ultrasound examination21,55-57. For example, in a recent study, ultrasound image 
attributes of subordinate follicles in cattle were correlated to oocyte competence57.  
Although image analysis is in an early stage of development, it demonstrates promise as a 
clinical tool to evaluate oocyte competence and physiologic status of a follicle in a non-
invasive manner56.  
We expected to observe marked differences in endometrial thickness and 
endometrial pattern between continuous and conventional dosing schemes, particularly 
during the hormone free interval.  However, both dosing schemes appeared to suppress 
endometrial development similarly.  Each cycle of conventional dosing was typically 
associated with four to seven days of menstrual bleeding.  We propose that similar 
endometrial patterns between dosing schemes was due to the high incidence of 
unscheduled bleeding observed during continuous dosing schemes.  It has been suggested 
that cycle control during continuous regimens increases with prolonged use5,8,17; further 
research is needed to determine if increasing the duration of continuous dosing schemes 
would result in markedly different patterns of endometrial development and unscheduled 
bleeding episodes with these OC formulations. 
In conclusion, continuous dosing schemes with 30 and 35 µg EE OC completely 
suppressed dominant follicle development better than the commonly used conventional 
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dosing scheme.  All follicular development was initiated during the hormone free interval.  
Continuous OC dosing did not allow development of dominant follicles, thus reducing or 
eliminating the possibility of break through ovulation.   We suggest that follicles which 
develop following discontinuation of OC have similar physiologic status to natural cycle 
follicles due to similarities in follicular diameter and the interval from dominance to 
ovulation.  The brief delay in ovulation following discontinuation of OC can not explain 
lower conception rates following cessation of OC. 
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Chapter 5 
GENERAL DISCUSSION 
Men and women have been preventing pregnancy and controlling their fertility 
through the use of many different forms of contraception for thousands of years210.  By the 
late 1800’s, many types of contraceptives were available in Canada, including but not 
limited to, abstinence, vaginal sponges, withdrawal, condoms, diaphragms, douching, 
prolonged lactation, the rhythm method, sterilization and abortion210.  These methods of 
contraception have improved greatly since their introduction, and are still used currently by 
many Canadians.   
It was not until the early 1960’s that oral contraceptives (OC) were introduced to 
the Canadian market; however, birth control was not legalized until 1969210.  Secular and 
religious stigmas against contraception were highly prevalent during the late nineteenth and 
early twentieth century.  Many of these stigmas presently continue to influence the large-
scale dissemination of information about different contraceptive choices such that the 
majority of Canadian women are unaware of most of their contraceptive options211.  
Canadians are interested in learning about new contraceptive choices; however, stigmas and 
personal embarrassment associated with sexual relations and contraception prevent many 
individuals from becoming informed.  
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The demand to manipulate human ovarian follicular development is on the rise.  
The number of women desiring contraception to inhibit pregnancy is increasing212.  
Ironically, the number of women requiring artificial reproductive technologies is also 
increasing213.  A better understanding of the physiologic mechanisms responsible for the 
growth, development and ovulation of ovarian follicles will allow us to understand how 
different hormones, factors and proteins can alter reproductive function, and this 
information would allow us to develop more acceptable, efficacious contraceptive 
techniques or new artificial reproductive technologies to improve pregnancy rates during 
infertility treatment. 
The studies contained in this thesis evaluated and compared the ultrasound image 
attributes of dominant ovarian follicles during natural and OC cycles; as well as, 
characterized changes in follicular and uterine development during the use and following 
discontinuation of two different OC dosing schemes.  The findings of these studies 
provide the rationale for further examination and development of image analysis 
techniques as a clinical diagnostic tool and the development of more efficacious OC dosing 
schemes. 
5.1 Follicular Development during Continuous and Conventional Oral 
      Contraceptive Use 
 
Administration of exogenous, synthetic estrogen in combination with different 
progestins causes atresia of follicles during the initial cycle of use, followed by suppression 
of follicular growth in subsequent cycles.  An OC primary mechanism of action is to 
prevent follicular growth and ovulation in 99.9% of users when taken exactly as directed109.  
However, “real-life” failure rates are reported to be up to 80 times higher (3-8%) than rates 
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reported for perfect use109,214-216.  The decrease in OC efficacy during “real-life” use is 
suggested to be due to many factors including: user non-adherence, not reading and/or 
misunderstanding product information, administration of OC with concomitant 
medication, gastrointestinal upset, high body mass index and inter/individual and intra-
individual metabolism of the exogenous hormones.   
User non-adherence accounts for approximately 20% of unintended pregnancies in 
the United States217.  Poor OC adherence includes missing doses, taking doses in the 
improper order, sporadic use, not using back up contraception when indicated and 
initiating a new package early or late217.  Up to 74% of women report missing ≥ 1 OC per 
28-day cycle175,176,178.  User non-adherence contributes to increased OC failure rates, 
bleeding irregularities and a three-fold increase in the risk of unintended pregnancy178,214,215.  
Furthermore, problems caused by non-adherence typically result in many women 
discontinuing OC and failing to use a substitute contraceptive, or adopting a less effective 
method177.  Non-adherence is particularly prevalent during the transition from one pill 
package to the next, an occurrence that takes place 13 times per year with conventional 
dosing schemes218.  The use of continuous dosing decreases the number of transitions per 
year which may lead to increased user adherence and a decreased risk of pill failure.  We 
suggest that an OC ought to be developed that has the ability to accommodate “real-life” 
use, while maintaining an efficacy rate of 99.9%. 
Follicular development during OC use is largely attributed to uninhibited 
gonadotropin suppression during the hormone free interval, such that by the end of the 
hormone free interval levels of FSH increase above the threshold for gonadotropin 
dependent follicular growth160.  Reinitiation of the next pill strip results in decreases in FSH 
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and subsequent atresia of most follicles; however, if a dominant follicle is present it may 
continue development to pre-ovulatory diameter and ovulation133,135,139,142,144,146,148,158, if the 
proper hormonal cues are present219.  We used high-resolution transvaginal 
ultrasonography to serially track and compare ovarian follicular development during the 
administration of continuous versus conventional dosing schemes to determine if replacing 
the hormone free interval with active dosing pills would better suppress follicular 
development than conventional dosing schemes, and thus provide a more efficacious OC 
(Chapter 4).  Continuous OC dosing schemes suppressed follicular development >4 mm 
better than conventional dosing schemes and completely prevented dominance from being 
manifest (Chapter 4).  Conversely, conventional dosing schemes allowed eight follicles to 
manifest dominance and two dominant follicles to subsequently ovulate (Chapter 4).  All 
dominant follicles initiated growth during the hormone free interval (Chapter 4).  We 
interpreted this data to mean, that continuous dosing schemes provide a more effective 
contraceptive than conventional dosing, by completely suppressing follicles from attaining 
dominance and ultimately preventing ovulation and subsequent OC failure. 
Follicles ≤ 4mm are not fully responsive to gonadotropins9,57.  Therefore, increased 
levels of gonadotropins associated with missed doses would likely have little effect on 
follicles ≤4 mm.  We observed very little follicular development >4 mm during continuous 
OC use compared to conventional use (Chapter 4).  We interpreted this data to mean that 
more consecutive doses of OC could be missed before follicular growth was initiated 
during continuous OC dosing schemes compared to conventional dosing schemes.  
Further research needs to examine the number of consecutive doses that can be omitted 
during continuous dosing schemes before follicular development >10 mm is observed. 
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A new model of follicular dynamics in women suggests that women develop two to 
three follicular waves of follicles ≥4 mm during each menstrual cycle56,149.  Waves of small 
antral (1-3 mm) follicles in bovine ovaries have been observed in association with 
circulating increases in endogenous FSH220. Furthermore, the dominant follicle can be 
identified retrospectively at 1 mm in diameter in bovine ovaries220. Since cattle are 
commonly used as human models it follows that follicular waves of small antral follicles 
may occur in humans98.  Currently, we do not know if OC suppress waves of follicular 
development.  Further studies should examine if OC suppress follicular waves, particularly 
waves of small antral follicles, as these follicles are generally not fully responsive to cyclic 
increases in gonadotropins.  Residual effects of previous OC use on follicular wave 
development should also be examined.  A further understanding of wave dynamics in 
humans may aid in the development of more efficacious OC that could target specific 
stages of follicular growth to prevent ovulation.  A contraceptive of this nature would 
decrease a women’s exposure to exogenous hormones by only administering hormones at 
key physiological time points, instead of throughout the entire ovarian cycle. 
We have documented that ultrasound image attributes of dominant follicles during 
natural and OC cycles are similar during the mid-to-late growth phase (Chapter 3).  Area 
under the curve, pixel heterogeneity and numerical pixel value were evaluated in the study.  
The only difference observed between the three image attributes was increased values of 
numerical pixel value for OC cycle follicles versus natural cycle follicles.  Although 
numerical pixel value were greater in OC cycle follicles, the increased values were not high 
enough to indicate poor physiologic status as described in studies using animal 
models101,221,222 .  Furthermore, follicles which develop to pre-ovulatory diameter during 
adherent OC use have markedly similar growth profiles and serum estradiol-17β levels to 
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natural cycle follicles at similar stages of development133,156. Taken together, we interpret 
this data to mean that follicles that develop under the suppressive effects of OC have 
similar physiologic function and ovulatory capacity as natural cycle follicles at similar stages 
of development.  Currently, we do not know why some pre-ovulatory sized follicles ovulate 
and others do not during OC use.  Further research should examine if luteinizing hormone 
secretion differs between women who do, and do not ovulate, during OC use.  Examining 
an association between luteinizing hormone secretion and ovulation would enhance our 
understanding of the physiologic mechanisms of action associated with OC use and aid in 
the development of an OC that could prevent ovulation in the entire population of women 
using OC. 
The health and viability of oocytes which develop during OC use has not yet been 
examined.  However, we suggest that oocytes which develop and ovulate during OC use 
have similar health and viability to natural cycle oocytes because pregnancies have been 
reported during OC use223,224.  Additional research should examine the health and viability 
of oocytes that develop during compliant OC use.  An appropriate animal model would 
need to be developed to examine the effects of exogenous synthetic estrogen and progestin 
on oocyte competence due to ethical constraints preventing research of this nature on 
human oocytes.  Results of a recent study performed in cattle, were interpreted to mean 
that image attributes of the follicle wall are correlated to oocyte competence222.  Further 
development of image analysis techniques could lead to a clinical tool that is capable of 
determining oocyte health and viability in a non-invasive manner during stimulation cycles 
for infertility treatment.  A clinical tool of this nature would have the potential to decrease 
the costs associated with infertility treatment and increase pregnancy rates by ensuring only 
competent oocytes were utilized during clinical treatment. 
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5.2 Menstrual Regulation during Continuous and Conventional Oral Contraceptive 
      Use 
Menstruation is simply a by-product of ovarian function.  OC were initially 
developed as menstrual regulators, and as such, had to induce menstruation once every 28-
day cycle.  Currently, most women believe that monthly menstruation is necessary to 
maintain reproductive health and that menstruation during OC use is due to the same 
physiologic mechanisms that induce menstruation during natural, spontaneous cycles123,125.  
Furthermore, women falsely believe that monthly menstruation during OC use confirms 
they are not pregnant and remain fertile123,125.  
Clinicians, researchers and anthropologists would argue that the current state of 
monthly menstruation is unnecessary to maintain reproductive health132,185.  For example, 
primitive women menstruated 66% less than the typical modern-day woman.  The increase 
in menstrual frequency in modern women is suggested to be due to evolutionary 
progression resulting in an earlier onset of menarche, later age of first birth, fewer 
pregnancies, shorter periods of lactation and a later onset of menopause compared to 
primitive women119.  The increased frequency of menstruation in modern day women and 
the associated large fluctuations in hormones, is thought to be associated with the 
development of many illnesses, including menstrual morbidity, endometriosis, anemia, 
uterine fibroids and cancers of the reproductive organs184.  It is suggested that the constant 
level of exogenous hormones provided by continuous OC dosing schemes and the 
associated state of amenorrhea is a healthier alternative to monthly menstruation because it 
would result in a decrease of many illnesses associated with hormone fluctuations and 
menstruation. 
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Women’s attitudes towards inhibiting menstruation are age and culture 
dependent116,183.  The percentage of women desiring amenorrhea increases with increasing 
age116.  Most women (81%) of Western or Western-oriented cultures desire a change to the 
duration or frequency of menses116,123,125,182, with approximately 40% of women preferring 
not to menstruate116,182,183.  Conversely, the majority (42- 71%) of African and Asian women 
would prefer to menstruate on a monthly basis, with only approximately 18% of these 
women preferring to inhibit menstruation183.  The most common reasons for wanting to 
suppress menstruation include: convenience, decreased menstrual related complaints, 
better hygiene, higher quality of life and less blood loss182; whereas, the desire to 
menstruate on a monthly basis appeared to be associated with strong cultural beliefs.  For 
example, most Nigerian women (81%) stated that monthly menstruation rids the body of 
bad blood183.    
Cycle control, defined as the occurrence of spotting or breakthrough bleeding is 
one of the key factors contributing to the acceptability of a contraceptive method225.  Poor 
cycle control is highly correlated to discontinuation of OC226.  Studies designed to compare 
bleeding characteristics of women using continuous versus conventional dosing schemes 
reported higher dropout rates in the continuous dosing group due to a higher incidence of 
unscheduled bleeding112,113,122.  Interestingly, most women who have administered OC in a 
continuous manner report preferring the inconvenience of unscheduled bleeding to 
monthly scheduled withdrawal bleeding112,113,115,122,123,227.  
We reported that women who used conventional dosing schemes experienced 
fewer days of unscheduled bleeding than women using continuous dosing schemes, during 
the first three cycles of OC use (Chapter 4).  Cycle control during continuous OC use is 
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reported to increase with increased duration of use, such that breakthrough bleeding is 
comparable between continuous and conventional dosing schemes containing ethinyl 
estradiol (EE) and levonorgestrel by approximately 9 months of use112,113,124.  We did not 
observe a decrease in unscheduled bleeding as the duration of OC use increased; however, 
the study design only permitted observation during the initial three cycles of OC use.  
Further investigations should examine the effects of prolonged continuous OC use on 
bleeding patterns and health. 
We did not observe a difference in cycle control during continuous or conventional 
dosing between levonogestrel and norgestimate (Chapter 4).  Cycle control is related to the 
half-life of the progestin; generally, the longer the half-life the greater the cycle control110.  
We suggest that similarities in the half-life (15 hours) of levonorgestrel and norgestimate 
are responsible for the similarities we observed in cycle control during both continuous and 
conventional OC dosing schemes (Chapter 4)110.    The dose of EE does not appear to 
effect cycle control during continuous OC dosing schemes112,124 (Chapter 4); however, few 
studies are available to compare the effects of the dose of EE on cycle control during 
continuous OC use.  It appears that continuous administration of exogenous EE and 
progestin during continuous OC dosing schemes maintains continual endometrial 
suppression and good cycle control which ultimately over rides the need for high doses of 
EE.   
The duration of continuous OC use and the type of progestin administered appears 
to effect the time required to induce amenorrhea.  Progestins are reported to directly exert 
their effects at the uterus; therefore, differences in bioavailability, serum half-life and 
relative binding affinity can alter the progestin’s effect on the uterus228.  The histologic 
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appearance of the endometrium during progesterone administration resembles that of an 
early pregnant uterus; the epithelium is thin and atrophic without mitosis, few blood 
vessels are present, the stroma is thick and decidualized, and the glands are poorly 
developed228.     
Comparison of studies which examined cycle control during continuous OC use 
with different OC formulation containing the same dose of EE but different progestins 
reveal that desogestrel and gestodene provide the greatest cycle control of all progestins 
tested.  Spotting and break through bleeding occurred less frequently with desogestrel and 
gestodene compared to levonorgestrel.  Furthermore, amenorrhea was induced in 81% of 
women within two consecutive 28 day cycles of 30 µg  EE / 75 µg gestodene and 52-75% 
of women were amenorrheic within two consecutive 28 day cycles of 30 µg  EE / 150 µg 
desogestrel115,117.  Only 42% of women were amenorrheic within 12 consecutive 28 day 
cycles of 30 µg EE/ 150 µg levonorgestrel112,227.  Furthermore, we did not observe 
amenorrhea during three 28-day cycles of continuous OC dosing of 30 µg EE/ 150 µg 
levonorgestrel or 35 µg EE/ 250 µg norgestimate (Chapter 4).  Superior cycle control with 
gestodene and desogestrel compared to levonorgestrel and norgestimate is likely due to 
gestodene’s and desogestrel’s higher affinity for progesterone receptors, a lower affinity for 
androgen receptors, a higher selectivity of action, and a higher potency at the level of the 
endometrium228.    
5.3 Return to Fertility following Discontinuation of Oral Contraceptives  
Oral contraceptives are the reversible contraceptive of choice of women in 
industrialized nations109.  Approximately half of Canadian women (49%) use OC as their 
method of contraception211.  Due to the high popularity of OC it is essential to determine if 
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OC have residual effects on ovarian function following their discontinuation.  It has been 
established that women who discontinue OC take two to three months longer to conceive 
than women who discontinue other types of contraceptive therapies (i.e., intrauterine 
device, diaphragm, or condom)195-204.  Few studies have examined the physiologic 
mechanisms responsible for the delay in fertility following discontinuation of OC. 
We used highly sophisticated transvaginal ultrasonography to serially monitor 
ovarian follicular development following discontinuation of both continuous and 
conventional dosing schemes (Chapter 4).  Most women ovulated following 
discontinuation of OC, suggesting that the two to three month delay in the return to 
fertility is not due to anovulation (Chapter 4).  Furthermore, we suggest that follicles which 
develop following discontinuation of OC have similar physiologic function to follicles 
which develop during spontaneous natural cycles due to similarities in follicle diameter at 
selection, dominance and ovulation as well as the time to ovulation once the follicle 
manifest dominance (Chapter 4).  Pre-ovulatory follicles that develop following 
discontinuation of OC are suggested to have equal potential to natural cycles to create a 
viable conception and pregnancy. 
Interestingly, follicles which developed following discontinuation of OC took 
slightly longer to be selected, manifest dominance and ovulate, compared to follicles which 
develop during spontaneous natural cycles (Chapter 4).  We suggest that this delay is due to 
wave synchronization of follicles during OC administration. During spontaneous natural 
cycles a cohort of follicles is recruited for growth and development during the late luteal 
phase, such that gonadotropin dependent follicles are commonly observed on Day 1 
menstruation.  The delay to ovulation following discontinuation of OC may be due to 
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follicular recruitment occurring before the first day of menses during natural cycles and 
after Day 1 in follicles following discontinuation of OC (Chapter 4).  The delay in 
ovulation was not great enough to explain the two to three month delay in fertility.  
Further research is needed to determine the exact physiologic mechanisms associated with 
the delay in fertility.   
5.4 Development of Novel Methods of Contraception 
 The once daily administration scheme of OC has a number of disadvantages, such 
as fluctuations of hormone plasma levels which can increase the incidence of hormone 
related side effects and increase non-adherence rates229. Many women regard the adherence 
required by daily OC to be a drawback to the use of OC and would prefer a contraceptive 
with a longer dosing interval229.  Women report that the ideal contraceptive would be: 
efficacious, safe, easy to use, have few side effects and provide excellent cycle control230.  A 
weekly transdermal patch containing norelgestromin and EE; (Ortho Evra: Ortho-McNeil, 
Raritan, NJ), and a monthly vaginal ring containing etonogestrel and EE (NuvaRing; 
Organon, West Orange, NJ) have been introduced within the past 5 years in response to 
women’s requests230. 
 The contraceptive transdermal patch delivers 20 µg EE and 150 µg norelgestromin 
to the bloodstream every 24 hours through a 20 cm2 transdermal patch231.  The patch is 
applied once a week for three consecutive weeks followed by one patch-free week158.  
Transdermal contraceptive patch use is reported to have higher adherence rates and greater 
cycle control while maintaining or increasing contraceptive efficacy compared to 
OC158,232,233 .   
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 The vaginal ring delivers 15 µg EE and 120 µg etonogestrel per day in a continuous 
manner such that daily peaks in serum concentrations are only observed at the beginning 
of each cycle compared to daily peaks observed during OC use230.  A cycle consists of 
wearing the ring vaginally for three consecutive weeks followed by removal of the ring for 
one week230; however, the vaginal ring maintains its efficacy for up to seven weeks of 
continuous use234,235.   
 New contraceptive methods such as the transdermal patch and vaginal ring are only 
the beginning of new contraceptive choices.  Both administration schemes provide patient 
acceptability equal to or greater than OC administration, suggesting that women are open 
to utilizing new, novel administration schemes as long as the schemes are easier to use, 
provide equal or greater efficacy, have few side-effects and maintain cycle control equal to 
or greater than OC.  Furthermore, bioavailability of the exogenous hormones is increased 
with these administration schemes because gastrointestinal metabolism and the first pass 
effect are avoided resulting in decreased doses required to maintain ovarian suppression 
and thus exposure to exogenous hormones is decreased229. 
 Modern day women are interested in new, novel contraceptive therapies; however, 
many modern women do not completely understand their own reproductive function, nor 
do they realize the number of contraceptive choices available to them211.  Health care 
professionals must ensure women are informed about their own reproductive function, 
contraceptive methods and how each contraceptive method effects reproductive 
functioning.  “Real life” OC use appears to decrease contraceptive efficacy.  The studies in 
this thesis are interpreted to mean that follicles that develop during OC use have similar 
physiologic function to natural cycle follicles, such that follicles that develop during OC 
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use are capable of ovulating resulting in subsequent pregnancy and pill-failure, if the 
secondary contraceptive characteristics of OC are not maintained.  New contraceptive 
methods ought to be developed to maintain extremely low failure rates during “real life” 
use.  Continuous OC dosing schemes, vaginal rings and transdermal patches all appear to 
be superior methods of contraception with respect to cycle control, ease of use, efficacy 
and associated side-effects compared to conventional dosing schemes.  Finally the return to 
fertility following discontinuation of OC does not appear to be due to lack of anovulation.  
Further investigations should examine the physiologic mechanisms associated with the 
delay in fertility following cessation of OC. 
5.5 Overall Conclusions 
The following hypothesis was not supported. 
1) Taken together, there was inadequate support for the hypothesis that ultrasound 
image attributes of human ovarian dominant follicles from natural cycles 
quantitatively differed from follicles which developed under the suppressive effects 
of OC. 
The following hypotheses were supported:  
2) Continuous OC dosing schemes better suppress follicular development than 
conventional OC dosing schemes due to greater hypothalamic-pituitary-ovarian 
axis suppression. 
3) Follicles take longer to ovulate following discontinuation of OC compared to 
natural cycle follicles. 
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